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SUMMARY
This thesis presents the results of a cross sectional clinical study of the PMN granule 
markers elastase and lactoferrin in conjunction with the major protease inhibitors alpha 1 
antitrypsin and alpha 2 macroglobulin in the gingival crevice. 10 subjects with chronic 
adult periodontitis were selected. Each subject had GCF collected from a healthy site, a 
gingivitis site and a periodontitis site. The samples were analysed by ELISA. Analysis 
of the date confirmed that the sites were separated on the basis of clinical findings.
With regard to the PMN granule markers, elastase was not able to discriminate between 
periodontal sites on the basis of absolute amounts or concentration whereas statistically 
significant differences were observed in relation to the absolute amount of lactoferrin at . 
healthy and periodontitis sites. The relationship between lactoferrin and elastase 
changed significantly when comparing healthy and gingivitis sites with periodontitis 
sites, where a 10-fold decrease in the relative release of elastase was noted. It is 
proposed that this relationship of PMN granule markers may be a useful indicator of 
periodontal breakdown. In addition it may indicate basic changes in the dynamics of 
PMN activity in the gingival crevice in relation to the disease state.
With regard to protease inhibitors, alpha 1 antitrypsin increased significantly in absolute 
amounts at sites of inflammation but remained unchanged in relation to its 
concentration. Alpha 2 macroglobulin increased at sites of inflammation in absolute 
amounts and was at highest concentration at sites of gingivitis. At sites of inflammation 
the amount of protease inhibitor relative to elastase increased. Thus, there was no 
evidence of a defective, host related protease inhibitor mechanism.
CHAPTER 1
INTRODUCTION
1.1 Definitions
The periodontium is the collective name for the tissues forming the attachment apparatus 
between tooth and bone. It comprises the four tissues:
• Radicular cementum
• Gingiva
• Alveolar bone
• Periodontal ligament
(Lindhe, 1989)
Together these tissues serve to anchor and suspend the teeth in the jaws. An important 
function of the gingival tissues is to form a physical barrier, mechanically sealing the 
interface between the oral cavity and the bone, thereby providing a primary defence 
mechanism against potential pathogens.
In relation to periodontal inflammation and the cells associated with acute inflammatory 
states, polymorphonuclear leucocytes, the anatomy of the gingival tissue is important. The 
gingival tissue covers the alveolar bone of the facial and lingual surfaces and encircles the 
teeth close to the amelocemental junction, where it is continuous with the junctional 
epithelium thus protecting the underlying tissue (Schroeder 1991).
Two zones are recognized macroscopically:
• Free gingivae - follows the scalloped contour of the necks of the teeth along the ACJ. The 
depth of the free gingiva is dependent on age and varies between 0.8-2.1mm in health.
• Attached gingivae - is bounded coronally by the marginal groove and apically by the 
muco-gingival margin. Again, its width is variable, being absent on the palate and widest
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over the maxillary lateral incisors. In health it appears pale pink and has a stippled 
texture, similar to the surface of an orange. This stippling represents indentations of 
connective tissue into the epithelium.
The gingival sulcus, or crevice, is the groove between the gingival margin and the tooth. It is 
open occlusally, the lateral surface of the tooth forms its inner boundary, the coronal 
portion of the JE its apical boundary and the oral sulcular epithelium its lateral wall. It is a 
very dynamic region.
The oral sulcular epithelium is structurally like the oral gingival epithelium with a 
stratified squamous, parakeratinised epithelium. This layer is not permeable to PMNs.
Non keratinised JE forms a collar around the tooth on the cervical enamel or cementum. It 
extends from the cemento-enamel margin to the bottom of the gingival sulcus in health and is 
continuous coronally with the oral sulcular epithelium. The JE is derived from the reduced 
enamel epithelium and consists of 1-3 cell layers apically, widening to 15-30 layers 
coronally. It has 2 distinct strata; the basal layer, which lies on the basal lamina and is 
mitotically active, and the supra-basal layer. The interface between the connective tissue 
and the basal epithelium is normally smooth and has few intercellular connections. 
Importantly, there are no diffusion barriers across these cells. The JE tissue is constantly 
renewed. Cells originate at the basal layers adjacent to the connective tissue then move 
suprabasally towards the tooth and coronally along the basal lamina in the process of 
renewal. They are ultimately shed into the gingival sulcus. The JE is capable of regeneration 
and reattachment in 5-7 days. At the base of the gingival sulcus the cells of the junctional 
epithelium are exfoliated. Due to a lack of diffusion barriers and the nature of the 
intercellular connections of the JE it is permeable. PMNs migrate continuously from the 
vessels in the gingival connective tissue into the crevice. The number of PMNs migrating 
varies widely and is primarily dependent on the degree of tissue inflammation.
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1.2 Periodontal Disease States
Periodontal diseases are inflammatory, bacterially induced conditions. They are recognized 
by a number of signs, dependent on the nature and severity of the disease. These include 
loss of periodontal attachment, bleeding on probing into the gingival sulcus, periodontal 
pocket formation, tooth mobility and tooth loss (Claffey 1994).
Periodontal disease, in one of its forms, has been reported to affect almost all of the 
population by adulthood (Marshall-Day et al 1955). It is advanced enough to pose a serious 
oral threat in a maximum of 10-20% of the population i.e. potentially to result in tooth loss 
(Papapanou .1994). Disease, severity on a population level, as indicated by periodontal 
pocketing of increased depth and extent, increases with age (Yoneyama et al 1988).
On the basis of clinical findings periodontal tissues can be defined as :
• Healthy
• Superficially inflamed, with inflammation confined to the soft tissues and not involving 
apical migration of the epithelial attachment or bone loss i.e. Gingivitis
• Periodontally involved, in which there is apical migration of the junctional epithelium 
and loss of the periodontal attachment apparatus.
1.2.1 Gingival Health
This is a state characterised by the lack of clinical signs of inflammation. The gingival tissues 
appear firm and stippled and are pale pink in colour. They have a scalloped outline with the 
gingival margin following the line of the ACJ. Bleeding on probing in the gingival sulcus is
4
absent. The JE is attached to the coronal enamel and terminates at the ACJ. The alveolar 
bone crest lies within 2mm of the ACJ.
Histologically the tissue is characterised by small numbers of inflammatory cells in the 
junctional epithelium and immediately sub-jacent. These are principally PMNs but also 
include macrophages, monocytes, lymphocytes and plasma cells (Page and Schroeder 1976, 
Lindhe and Rylander 1975).
The bacteria associated with periodontal health are generally Gram positive cocci with few 
motile organisms, i.e. Streptococcus sanguis, Streptococcus mitis, Actinomyces viscosus,
. Veillonella parvula, Actinomyces, naeslundi, Staphylococcus epidermidis (Socransky and 
Haffajee 1992).
1.2.2 Gingivitis
Gingivitis is inflammation of the gingivae. It is characterised clinically by oedema and 
redness of the marginal gingival tissues. There may be some loss of contour with 
interproximal swelling being present at an early stage. Bleeding on probing is present and the 
gingival crevice is deepened. It is present in most cases without underlying periodontal bone 
loss.
Gingivitis represents a tissue dynamic, whereby the host response confines the 
inflammatory process to superficial tissues. Irreversible tissue loss does not take place i.e. 
there is an effective host reaction which serves to limit and contain tissue damage (Attstrom 
and van der Velden 1994). The mechanism whereby this containment occurs is not yet 
understood. It is one of the major limiting factors in the successful use of markers to display 
periodontal activity as in only the minority of cases does gingivitis proceed to periodontitis.
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1.2.3 Periodontitis
Periodontitis involves inflammation and destruction of the supporting tissues of the tooth 
and is essentially characterised by apical migration of the JE and loss of alveolar bone.
Clinical features are variable depending on the age of the patient and the severity of the 
condition. Signs and symptoms include bleeding on probing into the gingival crevice, an 
increased clinical probing depth or loss of attachment and radiographic evidence of 
periodontal bone loss. Gingivitis may or may not be present. Pain is not generally a feature 
of the disease, but is present in some conditions i.e. acute necrotising periodontitis. 
Recession, tooth mobility and drifting may be present.
1.3 Aetiology of Periodontitis
Following the demonstration of a clear correlation between plaque accumulation and the 
development of gingivitis in experimental trials (Loe et al 1965, Seymour et al 1983), plaque 
is acknowledged to be the major aetiological factor in periodontal diseases' (Komman 1986). 
When plaque is allowed to accumulate on teeth or restorations at the gingival margin 
periodontal inflammation develops over a variable time span and with variable severity (Loe 
et al 1965, Socransky et al 1984).
Evidence for the existence of groups of individuals with higher susceptibility to the 
development of periodontal diseases has been presented (Johnson et al 1988). In their study 
of Sri Lankan tea workers Loe et al (1986) found 3 categories of subjects who could be 
identified; those with no attachment loss over the study period, those with moderate 
attachment loss and those with rapid attachment loss which resulted in tooth loss over the 
study period. This principle, of a range of periodontal susceptibilities, has been confirmed
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in a UK population. Cushing and Sheiham (1983) found deep pockets in only 7% of a 
British population. Some of this susceptibility may be genetically determined or related 
(Wilton etal 1988, Sofaer 1990).
The microbiology of plaques associated with periodontal diseases has been studied 
extensively (Moore 1987, Maiden et al 1990). Up to 400 species have been isolated from 
plaque samples and identified in association with disease or health (Socransky and Haffajee 
1992). The obvious problem is to discriminate between those organisms which are 
associated with disease and those which cause it. Socransky and Haffajee (1991,1992) 
discussed the important criteria for organisms in relation to periodontal diseases. They 
proposed that pathogens should have the following characteristics :
• be of a virulent clonal type
• possess the chromosomal and extra-chromosomal genetic factors to initiate disease
• that the host should be susceptible to the organism
• that the pathogen should be present in such numbers as to exceed the host threshold
to protect itself
• that the pathogen should be located in the correct place
• that other bacteria must foster, or at least not inhibit, the process
• that the local environment must be one which is conducive to the expression of the
species virulence properties
The principal concept now emerging in microbiological terms is one of bacterial ecology 
rather than specific infectious agents i.e. pathogenic plaques in the absence of protective 
species (Newman 1990). The bacteria most often implicated in periodontitis are 
Actinobacillus actinomycetemcomitans (Zambon 1985), Porphyromonas gingivalis, 
Prevotella intermedia (van Winkelhoff et al 1988) and spirochetes (Loesche and Laughon
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1982). For some organisms e.g. Actinobacillus actinomycetemcomitans and Porphyromonas 
gingivalis, a carrier status at healthy sites is reported. The overgrowth of these oral 
commensals above the level of the host resistance may be what leads to periodontitis 
(Theilade 1986). Preus et al (1987), reported cases of early onset periodontal disease in 
which sites with active bone loss harboured Actinobacillus actinomycetemcomitans with 
bacteriophage infection whereas those without bacteriophage infections had no active bone 
loss. Although the data they presented was anecdotal, they proposed this as a possible 
mechanism whereby commensal organisms become pathogenic.
Birkedel-Hansen (1993) proposed that bacterially induced damage is due partly to the 
release of proteolytic enzymes which destroy tissues directly. Bacterial products may also 
suppress local inflammatory responses e.g.Teukbtoxin production by Actinobacillus 
actinomycetemcomitans (Baehni et al 1979, Slots and Dahlen 1985). In addition to this 
independently mediated bacterial action bacteria produce toxins, LPS or enzymes which 
trigger macrophages, fibroblasts, keratinocytes and endothelial cells. The final pathway of 
tissue destmction in periodontitis is dependent not only on direct bacterial action but also 
on the release from triggered host cells of inflammatory mediators (Slots and Genco 1984).
Direct tissue invasion associated with diseased tissue has been demonstrated in acute 
necrotising ulcerative gingivitis (Listgarten 1965, Loesche et al 1982). Other reports of 
tissue invasion have been questioned as artefactual, being caused by sampling techniques 
which introduce bacteria. Recently the ability of bacteria to invade cells in culture has been 
demonstrated (Sandros et al 1993, 1994). This capacity to invade tissue has been associated 
with clinical difficulties in the elimination of bacteria and treatment of disease (Saglie et al 
1981).
The host has several superficial protective mechanisms (Genco and Slots 1984). These 
include; prevention of bacterial colonisation, the integrity of the junctional epithelium as a
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physical barrier, the flow of GCF and desquamation of cells and the release of toxic or 
irritant substances by bacteria in the crevice.
Beyond the superficial defence the provocation of local inflammatory and immune 
responses occurs. The inflammatory reaction is mounted initially by PMNs in the gingival 
crevice. Examination of individuals with abnormal PMN responses, either qualitatively or 
quantitatively, shows that these individuals have early onset or rapidly progressing 
periodontal breakdown compared with those without such defects (Wilton et al 1988). In 
view of the poor outcome if PMNs are not functioning the potentially damaging effects of 
these cells is accepted as collateral damage and the cells appear to be of clinical benefit. 
Other facets of the host response rely on the actions of T cells in cell mediated immunity, B 
cells and plasma cells in antibody production and monocytes and macrophages in the 
elimination of bacteria (Ranney 1991).
Recent evidence regarding the effect of cigarette smoking has shown this is of major 
importance in terms of susceptibility to disease and difficulties in its treatment (Haber et al 
1993, Bergstrom 1994). Smokers have been shown to have more bone loss (Amo et al 1959) 
than non smokers, a poorer response to treatments, both surgically and non surgically 
(Preber and Bergstrom 1985,1990), with this difference being more marked when 
sophisticated treatment is provided. The mechanism for this susceptibility to disease and 
resistance to treatment is not understood, but is thought to have both local and systemic 
components and to be unrelated to plaque (Bergstrom et al 1991). In lung disease cigarette 
smoking is proposed to have a role in the oxidation of alpha 1 antitrypsin, disabling it and 
reducing the protective screen against elastase in the alveolar tissue (Gadek et al 1981);
Alavi et al (1995) proposed a similar mechanism in the periodontium.
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Local factors e.g. crowded teeth, mouth breathing have been proposed as of importance in 
the aetiology of periodontal disease. These are now thought to contribute to damage by the 
promotion of plaque accumulation but not by altering the host susceptibility.
Despite knowledge of the aetiology of periodontal tissue loss there still exists no reliable 
method for the prediction or immediate detection of clinical disease. Several theories 
regarding the temporal nature of tissue loss have been proposed. Epidemiological data 
supports the concept that periodontal attachment loss is progressive with age 
(Papapanou 1994), this was proposed as the slow continuous pattern (Socransky et al 
1984). Socransky et al (1984) disputed the validity of this model on the basis of the 
clinical findings when monitoring longitudinal attachment loss. They suggested that 
attachment level changes were not continuous but rapid and of short duration, in addition 
that they were random in distribution. The development of their alternative model came 
about largely because of the difficulties involved in longitudinal monitoring of attachment 
loss and the probing differences required to reliably diagnose that this had occurred. With 
the more widespread use of the Florida probe the threshold for recognising changes in 
attachment level is reduced and the concept of random quick periods of attachment loss is 
being disputed. Despite improvements in the reliability of periodontal probing, the search 
is still underway for a clinically useful test to diagnose periodontitis before irreversible 
tissue damage occurs.
1.4 Gingival Crevicular Fluid
Gingival crevicular fluid is fluid which can be recovered from the gingival crevice. It is 
derived principally from serum and contains cells, bacteria and tissue products. It has been 
estimated that between 0.5 and 2.4 ml of GCF flows into the oral cavity per day (Cimasoni
1983).
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Several theories of formation for GCF have been proposed. Brill and Krasse (1958), Brill 
and Bjom (1959) and Egelberg (1966), related GCF production to inflammatory changes in 
the connective tissue vessels underlying the JE resulting in leakage of serum. They suggested 
that the permeability of JE regulated fluid flow outwards into the gingival crevice to form 
the GCF.
Alfano (1974), proposed that the flow of GCF was due to the effects of osmotically active 
substances in the gingival crevice e.g. plaque products. Under normal circumstances these 
products, in small amounts, would be removed by absorption onto desquamating epithelial 
cells and would have a small effect. At sites of plaque accumulation, the normal turnover of 
epithelial cells forming this local defence would be insufficient to control the accumulation 
of osmotically active products. Thus, macrdmolecules could diffuse intercellularly and 
accumulate at the basement membrane establishing an osmotic gradient between the crevice 
and the connective tissue. This gradient would promote the flow of fluid from the 
connective tissue. The innate permeability of the junctional epithelium is again of crucial 
importance in this theory.
Pashley (1976), described a model for GCF production which postulated that GCF 
production was a balance between passage of fluid from capillaries into tissue and its 
subsequent uptake by lymphatic vessels. If the balance is altered, increasing the filtration 
rate from capillaries to a level above that of the lymphatic drainage rate, fluid accumulates in 
the interstitial fluid compartment, crosses the basement membrane and JE and passes into 
the gingival crevice.
GCF contains cells, electrolytes, organic compounds including carbohydrates, 
immunoglobulins, complement, lipids, cell metabolites, bacterial products and enzymes 
(Cimasoni 1983). Of most interest in the present study is the cellular content.
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Loe (1961) reported the cellular component of GCF to be epithelial cells, shed from the JE, 
and leukocytes. Attstrom and Egelberg (1970) reported the differential leukocyte count in 
the gingival crevice as PMNs 95-97%, lymphocytes 1-2%, monocytes 2-3%. By far the 
most prominent cell type in GCF is the PMN. When recovered approximately 80% of 
PMNs are viable (Skapski and Lehner 1976) and possess residual phagocytic capacity 
(Kowolik and Raeburn 1980, Thurre et al 1984). The numbers of white cells emigrating from 
blood vessels through the junctional epithelium and into the sulcus increases with the degree 
of inflammation in the gingival tissues (Attstrom 1970, Loe and Silness 1963, Adonogianaki 
et al 1993, Kowashi 1980, Thurre et al 1984, Schiott and Loe 1970). In vitro and in vivo 
studies have demonstrated the ability of supragingival plaque to increase PMN migration, 
increase vascular permeability in the dentogingival vessels and increase GCF flow (Hellden 
and Lindhe 1973) i.e. to be chemotactic.
The majority of GCF is plasma derived with local conditions altering the rate at which fluid 
leaves capillaries. The permeability of the junctional epithelium enables the passage of fluid, 
cells and cellular products into the gingival crevice. What is contained in the GCF eventually 
entering the crevice varies according to the local conditions, thus is of interest as a potential 
source of disease markers.
1.4.1 Collection of GCF
Several methods of collection of GCF have been described. The various methods to consider 
are:
• Use of absorbent paper strips
• sampling with micropipettes
• collection of gingival washings
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Each of these methods have slight differences in technique which makes their application 
suited for some investigations rather than others. The present study employed the use of 
absorbent paper strips and this technique will be discussed further.
Brill and Krasse (1958) described collection of GCF using absorbent strips. In the extra 
crevicular method strips are placed over the orifice of the gingival crevice on the vestibular 
surface of the teeth, marginal and attached gingivae. This method avoids all trauma to 
sulcular and junctional epithelium during collection but involves the risk of salivary 
contamination of the strip. In contrast, intra crevicular sampling involves placing the filter 
strip into the gingival crevice until resistance is felt. The strip is placed atraumatically to 
avoid contamination.
Griffiths et al (1988) compared filter strips and assessed their suitability with regard to 
GCF collection and compatibility with the Peritron 6000, used in the estimation of GCF 
volume. They found the absorbency of Whatmann 3MM chromatography papers allowed 
high uptake of fluid prior to saturation when compared with Periopapers. In addition they 
showed good recovery of serum proteins following elution over a wide volume range from 
these strips.
Nakashima et al (1994) compared the recovery of PMNs and enzymes from Periopaper, 
Whatmann 3MM chromatography paper, paper points and Durapore filter membranes. All 
materials except paper points released more than 90% of sampled enzymes into saline and 
were considered satisfactory for the recovery of GCF enzymes.
Durapore filters have been shown to be useful for the recovery of intact PMNs from the 
gingival crevice (Andersen and Cimasoni 1993). They reported a recovery rate of around 
90%, with cells being easily removed from the Durapore during elution compared with other
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strips tested. They proposed that collection of GCF using Durapore filters was valuable for 
direct evaluation of PMN number and enzyme levels in the same sample.
The length of sampling time affects the composition of GCF and times varying between 5 
seconds and 3 minutes have been suggested (Loe and Holm-Pedersen 1965, Biswas et al 
1977, Hattingh and Ho 1980, Novaes et al 1980, Curtis et al 1988). The most commonly 
employed sampling time is 30 seconds. This appears to cause little trauma or alteration in 
the dynamics of the crevice while enabling collection of adequate quantities of GCF for 
examination (Lamster et al 1986).
Quantification of the. volume of fluid collected from the crevice has been carried out by 
weighing of the strip (Valazza et al 1972), estimation of the amount of wetting of the strip 
(Golub et al 1971, Egelberg and Attstrom 1973) and now commonly with the Periotron. The 
Periotron is an instrument which measures the electrical flow between its upper and lower 
jaws when a moistened paper strip is placed between them. The flow is a reflection of the 
degree of wetting of the paper. This can be calibrated against known volumes of fluid and 
the appropriate conversion made to give the volume of GCF. When used consistently, with 
standardisation of strip placement and daily calibration this method has proven useful and 
reliable (Hinrichs et al 1984, Stewart and Maeder 1986, Stewart et al 1993). Recently, 
however, Chapelle et al (1995) reported that at sample volumes below 0.2ul the reliability 
of the Periotron 6000 was greatly reduced. The differences in fluid volume readings between 
machines was significant. In addition to the unreliability of the Periotron with small 
volumes, problems occur due to evaporation from strips (Curtis et al 1988). When small and 
dissimilar sample volumes are being compared, this has a proportionately large effect on 
volume measurement and may be significant when calculating concentrations of constituents 
in GCF (Lamster et al 1986, Imrey 1986). These findings further supports the reporting of 
absolute amounts of GCF constituents rather than concentrations in clinical trials.
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1.5 GCF as a source of periodontal markers
The clinical difficulties in identifying periods of disease activity has led to the search for 
markers of disease which are sensitive to changes in the local environment or which 
precede the clinical changes. Due to the contribution of locally derived components to 
GCF it has been proposed as a major source of this information (Fine and Mandel 1986, 
Curtis 1989 et al, Harper et al 1989, Lamster 1991, Lamster 1992, Offenbacher et al 1993, 
Lamster et al 1994, McCulloch 1994). Proposed markers are related to aspects of the 
pathogenesis of the disease as outlined above. Curtis et al (1989) defined the potentially 
useful components of GCF:
• Products derived from microbial plaque e.g. endotoxin, enzymes and end products
• Products of tissue breakdown e.g. collagens, proteoglycans, hyaluronic acid and 
other CT components
• Products of host cells e.g. desquamating epithelial cells and leukocytes, enzymes 
such as collagenase, elastase, cathepsin D, lysozyme, hyaluronidase, B- 
glucuronidase, aryl sulphatase and lactoferrin.
• Products of host immunity e.g. immunoglobulins, complement, IL1 and IL8, and 
arachidonic acid metabolites.
Modem laboratory methods have made identification of indicators much easier, especially 
where only small quantities of the component being examined exist. The number and range 
of substances which can be identified in GCF has increased greatly and commercial kits are 
now available. These kits rely on the quantification of one aspect of the pathogenesis of the 
disease process e.g. microbiology or cellular processes. However, they discriminate between 
inflammation and no inflammation, but not between the superficial inflammation in gingivitis 
and inflammation associated with the destruction in periodontitis. Recently the concept of a
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risk profile, based on the incorporation of several markers within GCF has been developed 
(Lamster 1994 et al). Grbic et al (1995) combined immunoglobulin profiles and a PMN 
marker in GCF and suggested that such a profile was useful in the investigation of the host 
response. The developement of marker profiles may prove more useful than the use of 
single indicators in isolation. It is on the basis of the developement of a GCF profile of 
PMN degranulation at different categories of sites that the present study is based.
1.6 Polymorphonuclear leukocytes
The polymorphonuclear leukocyte is a phagocytic cell and is the predominant leucocyte 
in blood and in the gingival crevice (Attstrom & Egelherg L970, .Wilton 1986 and Bedeck 
Spat et al 1991). It forms about 62% of peripheral white blood cells and about 91% of 
gingival crevicular cells recovered by aspiration (Skapski & Lehner 1976). PMNs are 
found at sites of both gingival health and disease (Sharry & Krasse 1960, Attstrom & 
Egelberg 1970). The PMN is an important cell because, along with the integrity of the 
physical surface barrier, it forms the first line defence against invading pathogens.
PMNs develop from pluripotential bone marrow stem cells (Bainton et al 1971) and the 
cells go through several stages prior to maturity. The lifespan of a PMN outwith bone 
marrow is short, with an average of 7 (McGee et al 1992) to 58 (Bainton et al 1971) hours 
reported. The production of PMNs and their release from the bone marrow is closely 
controlled by colony stimulating factors, each of which controls a specific stage of 
maturation, amongst these are Interleukin 3, the complement fragments C3e and C3d.g, 
Granulocyte and Macrophage CSF, Interleukin 6, Granulocyte CSF, Monocyte CSF and 
Erythropoitin (Kanwar and Cairo 1993).
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As PMNs mature they become more deformable, alter their surface charge and acquire 
new cell surface receptors (Wallace et al 1987). Following these changes mature PMNs 
can cross endothelial barriers in the bone marrow and enter the bloodstream.
In the circulation PMNs form two pools; circulating and marginated (Athens 1981). 
Marginated PMNs are ‘stored’ in the small vessels, particularly of the lung and spleen. 
They can be mobilised at short notice in times of acute need. The average range of PMN 
numbers in the circulation is 2.5-1.5 xlO9  cells/litre. The number can increase 10 fold 
within 28 hours in times of acute inflammation. This rapid and substantial increase in 
PMN number occurs as a result of several processes; transfer of cells from the marginated 
to the circulating pool, increased release of mature cells from the bone marrow and an 
increase in the rate of maturation o f cells within the bone marrow. Numerous surface 
receptors are present on PMNs (Rosales and Brown 1993). Four major classes are 
identified; receptors for inflammatory mediators and bacterial products, receptors for 
lymphokines and monokines, opsonic receptors and receptors for endothelium and 
proteins of tissue matrix. These receptors are used for all stages of PMN emigration from 
blood vessels, chemotactic movement, recognition of foreign materials, its binding and 
phagocytosis and for the control of these processes via lymphokines and monokines.
The PMN has a characteristic light microscopic appearance with a multilobed nucleus and 
numerous cytoplasmic granules. It has a diameter of 12-15a. The granular component of 
the cell consists of many cytoplasmic granules with an outer membrane enclosing the 
densely packed protein in a mucopolysaccharide matrix.
Three types of granules exist
• primary or azurophil granules (Bainton et al 1971)
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• secondary or specific granules (Bainton et al 1971)
• tertiary or C particles
The tertiary granule is not well characterised and is thought to contain gelatinase 
(Miyasaki et al 1994). Granule contents have been investigated by many workers 
(Baggiolini et al 1978, Spitznagel et al 1974, Bainton et al 1971, Falloon & Gallin 1986).
1.6.1 Primary Granules
Primary granules are first formed, at the promyelocytic stage, and develop within the 
Golgi apparatus and rough ER. They are identified by their peroxidase content. Positive 
staining for peroxidase is seen in the granules, at all stages, and in the PMNs secretory 
apparatus during their formation. The degree of peroxidase compaction is variable. Their 
appearance is not uniform, granules are either round or shaped like a rugby ball, with 
round granules predominating. Primary granules contain (Baynes and Bezwoda 1994):
Antimicrobial Agents Defensins
Myeloperoxidase 
Lysozyme 
Cationic proteins 
Proteinases Elastase
Cathepsin G
The contents of the primary granules are largely responsible for the non oxidative killing 
mechanisms of the neutrophil (Miyasaki et al 1994)
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1.6.2 Secondary granules
Secondary granules are formed at the myelocyte stage of PMN developement, after 
primary granules. They are peroxidase negative, of low density and are twice as numerous 
as primary granules in the mature PMN. Their size is variable and they are typically 
spheres or rods. All secondary granules have a similar content despite their morphological 
differences. Secondary granules contain (Baynes and Bezwoda 1994):
Antimicrobial agents Lysozyme
Proteinases Collagenase
Other Lactoferrin
B 1 2  binding protein 
Laminin receptor(67K)
CD1 lb/CD 18 (C3bi)
Fibronectin receptor alpha 
Vitronectin receptor alpha
The release characteristics and kinetics of primary and secondary granules are different. 
Secondary granules are released chiefly extracellularly, with the granules being found close 
to the advancing edge of cells responding to a chemotactic stimulus (Wright and Gallin 
1979). Evidence of secondary granule release extracellurlarly is more prominent than that 
of primary granule release (Henson 1971) and occurs at an earlier stage (Bentwood and 
Henson 1980, Gustafsson et al 1994). These phenomenon have been interpreted in the 
past as indicating a secondary and extracellular function of secondary granules and an 
intracellular function of primary granules related to phagocytosis (Wright and Gallin 
1979).
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The process of degranulation is calcium dependent and is not related to cell death (Henson 
1971, Wright and Gallin 1979 and Taichmann et al 1977) with lysozymal enzymes 
released without a rise in lactate dehydrogenase, an indicator of cell death. In vitro, granule 
release can be stimulated by dental plaque (Taichman et al 1977), binding of immune 
complexes and complement (Henson 1971(a)), binding to non phagocytosable surfaces 
(Henson 1971(b)) and passage through membranes (Wright and Gallin 1979).
1.7 Polymorphonuclear Leukocytes in Inflammation
When functioning efficiently against infectious agents PMNs leave blood vessels and 
move, across tissues towards, a chemotactic source where they attempt to kill the 
organism.
Adhesion molecules related to the movement of PMNs from vessels are expressed on 
endothelial cells and PMNs (Rosales and Brown 1993). During inflammation the 
molecules which are important for the binding of PMNs appear before those for other 
leukocytes, thus PMNs are the first cells to cross the vessel wall. The immediate adhesion 
of PMNs is mediated via upregulation of P-selectin on endothelial cells by thrombin or 
histamine (Patel et al 1991). Stimulation of post capillary venules by inflammatory agents 
or bacterial markers, including IL-1 and TNF, stimulates protein synthesis, upregulating 
the expression of the endothelial cell markers (Diamond 1991, Staunton et al 1990). This 
functions over the longer term i.e. 24 hours and increases the interaction of leukocytes 
with the cells of the vessel walls. The endothelial markers ICAM-1, ICAM-2 and 
VCAM-1 bind to the LeuCAM family of integrins which are expressed on PMNs. LFA-1 
binds specifically to ICAM-1 and ICAM-2. MAC-1 also binds ICAM-1.
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In response to the expression of surface markers the cells change shape and roll along the 
blood vessel wall. They eventually stop moving, become flat and their membranes 
develop a ruffled border. They then migrate through the endothelial wall. ELAM-1, which 
is necessary for this migration, is expressed in response to IL-1 and TNF. IL-1 and TNF-a 
thus have a crucial role in the control of inflammatory mechanisms following the initial 
stimulus (Page 1991).
PMNs are capable of responding to many different chemoattractants including N-formyl 
peptides, complement derived C5a, Leukotriene B4, interleukin 8  and platelet activating 
factor (Havarth 1991). Chemoattractant receptors span the cell membrane and are 
GTPase-coupled receptors. The intermediary G proteins of these receptors couple cell 
surface binding of the Chemoattractant to the final effector enzyme systems of the PMN. 
The rate of conversion of GDP to GTP in the receptors serves to control the processes 
started by the initial cell surface binding of ligand.
Once outside the vessel, cells migrate through the connective tissue towards the 
chemotactic stimulus. Directed movement of PMNs comes about by the interaction of 
specific chemoattractants with surface receptors on its plasma membrane. Binding 
activates a cascade of secondary intercellular events which lead to either chemotaxis or the 
respiratory burst, dependent on the chemotactic agent (McPhail and Harvath 1993).
Neutrophils stimulated by chemoattractants undergo morphological changes becoming 
elongated cells with a ruffled border. During movement the anterior edge extends forwards 
and the posterior edge retracts towards the body of the cell (Cassimeris and Zigmond 
1990). When attached to a substratum their advancing edge is directed towards the 
chemotactic stimulus and the contractile end posteriorly. Adherence of the cells to a 
substratum occurs via the glycoproteins and proteoglycans of the ECM. The 
concentration of ECM glycoproteins and proteoglycans changes at sites of gingival
21
inflammation (Bartold 1992, Purvis et al 1984) and these molecules can become 
chemotactic for inflammatory cells. Actual cell movement occurs by the polymerisation of 
globular actin to fibrillar actin and current models propose that the fibrillar actin is 
involved in the generation of the force required for cell movement (Onman et al 1987).
Chemoattractant receptors exist in two interconvertible forms; high and low affinity states 
(Sklar and Onman 1990). At high affinity sites the ligand slowly dissociates from the 
receptor whereas at low affinity sites dissociation is rapid. Chemotaxis is initiated at 
receptors by concentrations of chemoattractants which are much lower than those 
required to produce the respiratory burst. Snyderman and Pike (1984) proposed that 
binding of chemoattractant to high affinity sites results in chemotaxis whereas binding to 
low affinity sites results in degrariulation. Kermbde et al (1991) proposed that binding to 
a receptor converts it to a high affinity state which then results in degranulation. If the 
ligand has a high binding affinity or is extremely stable then binding is maintained. The 
maintenance of this state is necessary for chemotaxis. If the ligand is of low potency then 
the high affinity state is not sustained and chemotaxis does not take place. This difference 
in the effect of chemoattractants is known as chemoatracttant divergence (Havarth 1991).
It has been suggested that endogenously generated chemoattractants recruit neutrophils to 
inflammatory sites with minimal activation of the respiratory burst. This provides a 
mechanism which maintains tissue homeostasis while preventing damage to the host 
tissue during neutrophil migration. Chemoattractants generated by invading organisms are, 
in contrast, more potent stimuli of both chemotaxis and oxidative metabolism in the 
PMN, as occurs in an infectious environment in vivo. Chemoattractants appear to be 
most effective in producing chemotaxis in the following order of potency; IL-8 , LTB4, 
C5a, FMLP, PAF. For the production of the respiratory burst the following order of 
potency applies; FMLP, C5a, with PAF, IL8  and LTB4 all of similar effectiveness 
(McPhail and Havarth 1993).
22
Once at the site of the chemotactic stimulus and prior to attachment of the PMN to the 
invading organism, opsonisation takes place. Opsonisation can take place either in the 
presence or absence of complement and antibody.
In the presence of complement and antibody, activated C3 and IgG bind their respective 
PMN receptors, CR1 and CR3 for complement and FcRl 1 and FcRl 11 for antibody.
Capsular organisms are able to evade this opsonisation and phagocytosis due to the 
masking of the antigenic portion of their cell wall by the capsule and by avoiding the 
deposition of complement on their surface (Finlay and Falkow 1989, Slots and Genco 
1984, Arnold 1993)..................................................................................................................
If antibody or complement are not available then alternative systems exist for the 
opsonisation of bacteria. Generally, cell wall antigens determine the ease with which an 
organism is phagocytosed. Lipopolysaccharide binding protein is an acute phase reactant 
which binds LPS. LPS is a cell wall component of gram negative bacteria. The binding of 
LPS binding protein to bacteria enables binding to the CD 14 receptor on PMNs and 
macrophages thus enhancing phagocytosis (Wright et al 1989). Since gram negative 
bacteria are abundant in the gingival crevice and complement and antibody can be locally 
destroyed (Genco and Slots 1984) it is likely that this system is in operation.
Following opsonisation phagocytosis can occur. Phagocytosis is the process by which the 
PMN takes up a particle. It involves attachment of the phagocyte to the particle and its 
subsequent engulfment. It starts with the receptor-ligand binding between PMN and the 
microbe. This interaction activates the ingestion phases which involve actin, myosin and 
actin binding proteins. Actin microfilaments in the portion of the cytoplasm underlying 
the site of particle attachment undergo polymerization. This polymerization leads to
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puckering of the plasma membrane at the site of contact where microfilaments are 
attached. The membrane surrounds the particle, pseudopodia are produced and a 
phagocytic vacuole is formed. Simultaneously cytoplasmic granules fuse with the 
phagosome membrane to form a phagolysosome. This final fusion of the membranes and 
release of granule contents generally results in destruction of the engulfed particle 
(Verhoef and Visser 1993).
Once phagocytosed and engulfed by the PMN 2 mechanisms exist to kill the organism; 
oxygen dependent and oxygen independent mechanisms (Van Dyke et al 1985).
Oxygen.dependent killing is. activated when the PMN undergoes a respiratory burst - 
coincident with phagocytosis. NADPH in the phagolysosome membrane is activated and 
reduces 0 2to superoxide (Weiss 1989).
The proposed sequence of activation of the NADPH oxidase complex is illustrated below:
1) 2 0 2  + NADPH ■> 2 0 2‘ + NADP+ + H+
NADPH oxidase
2) 2 0 2' + 2 H+ > h 2 o 2  + 0 2
3) The Haber Weiss reaction:
0 2- + h 2 o 2 ■> OH’ + OH + 0 2
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The third step in this sequence is often discussed but has never been demonstrated in 
vivo. Following the generation of hydrogen peroxide and OH in this reaction it is 
proposed that a second enzyme system involving myelperoxidase, a primary granule 
component, becomes active. Myelperoxidase is released by PMNs in large quantities but 
on its own has little effect. In combination with H2 0 2  myeloperoxidase is capable of 
catalysing the oxidation of plasma halides, the most important of which is chloride 
because of its concentration.
H2 0 2  + Halide + H+ > HOX + H20
(X) myelperoxidase (halide)
It is at this stage that the interaction between chlorinated oxidants, protease inhibitors and 
proteases can occur. Alpha 1 antitrypsin contains a methionine residue which is sensitive 
to oxidation, resulting in a 2000 fold decrease in its association with elastase. Weiss 
(1989) proposed that chlorinated oxidants produced as a result of the 
NADPH/myeloperoxidase reactions, oxidate the protease inhibitor, thereby creating a 
zone in which extracellularly released elastase can directly act on its substrate. Once 
bound to its substrate, elastase is insensitive to further inhibition by protease inhibitors. 
This mechanism was also proposed in relation the other major protease inhibitor alpha 2 
macroglobulin. The importance of this system in the immobilisation of protease inhibitors 
in vivo is however now questioned.
In vivo, in the presence of iron, H2 0 2  and superoxide, an alternative to the above Haber- 
Weiss reaction, the Fenton reaction, is proposed (Morris et al 1995). OH production from 
H2 0 2  and 0 2  is dependent on iron availability, with iron being reduced to Fe2+ during the 
reaction. OH is considered the most toxic of all the free radicals. If this reaction occurs in 
vivo then the rate limiting step is the availability of iron. Little free iron is available due to 
its binding to transferrin and lactoferrin extracellularly and apoferritin intracellularly
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(Sanchez et al 1992). In the phagocytic vacuole the pH is reduced and some iron may be 
lost from transferrin, however, lactoferrin retains its ability to bind iron at pH4 thus 
protecting the cell and limiting the production of OH (Halliwell and Gutteridge 1985).
Oxygen independent killing is based on the PMN granule network. Antimicrobial agents 
which are independent of 0 2  are released into the phagolysosome during phagocytosis 
(Thomas et al 1988). These granule components, including bactericidal/permeability- 
increasing protein, chymotrypsin-like cationic protein and defensins (Weiss et al 1982, 
Verhoef and Visser 1993) and those outlined above, are strongly bacteriocidal and in most 
cases effectively kill bacteria (Miyasaki et al 1994). In addition to killing bacteria the 
proteolytic enzymes, including elastase and the metalloproteinases have the potential to 
damage extracellular tissue and have been suggested to operate in periodontal tissues 
(Ohlsson et al 1974, Sandholm 1986, Birkedal Hansen 1993,1994)
1.8 Granule Components
1.8.1 Elastase
Elastase is a serine protease, a member of the family of neutral proteases which includes 
Cathepsin G and collagenase and it is found in and released from primary granules. It was 
identified by Janoff and Schrerer (1968) and has a molecular weight of 27-31,000 with 
variable carbohydrate content. The mRNA for elastase is found in PMNs only up to the 
promyelocyte stage, following which production of the components of the primary 
granule ceases (Bainton et al 1971). Elastase is not present in all primary granules, but is 
found in a ratio of 400+ve per 1500 granules. PMNs not containing elastase are not 
morphologically different, but can be identified by density gradient centrifugation.
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Elastase has many potential actions, reviewed and discussed by Woesner (1992), 
Cergeneux et al (1982), Ohlsson & Olsson (1974). In vitro these properties include 
cleavage of elastin, which has been demonstrated for elastase in GCF; degradation of 
types I, III and IV collagen, all of which are present in basement membrane and 
periodontal tissue; proteoglycan cleavage; fibronectin cleavage; degradation of complement 
factors, IgG, kininogen and clotting factors VIII, XII and XIII. In vivo, the functions of 
elastase are less clear.
The in vivo action of elastase is closely related to its binding with protease inhibitors 
(Ohlsson and Olsson 1974, Weiss 1989, Lamster 1991, Woessener 1992, Giannopolou et 
al 1992). The major serum protease inhibitors are alpha 1 antitrypsin, alpha 2 
macroglobulin and secretoryTeukoprofeiriase inhibitor. Alpha 1 antitrypsin and alpha 2 
macroglobulin have been identified in GCF (Ohlsson et al 1974)
Elastase is important in several disease processes (Leff and Repine 1993), particularly 
adult respiratory distress syndrome (ARDS). ARDS is a noncardiogenic, pulmonary 
oedema that occurs as a result of non specific damage to the alveolar capillary membrane. 
As a result of the damage, alveolar spaces are flooded with inflammatory cells. Bronchial 
lavage studies in patients with this condition have shown a large increase in levels of 
neutrophil products, notably elastase (Gadek et al 1981). Lieberman (1976) suggested that 
the damage in ARDS is brought about by an inbalance of the protease-antiprotease shield 
in the lung. Wewers et al (1988) demonstrated that the neutrophil elastase activity in 
ARDS lavage fluid was produced by elastase complexed to alpha 2 macroglobulin. They 
further suggested that although the complex was active against low molecular weight 
substrates, it was unlikely to be involved in tissue damage in vivo, but rather to function 
in immunomodulation.
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In GCF elastase has been studied as a marker of diseases in two directions; the protease 
activity of elastase-like peptides and antigenic elastase content. Potentially these are two 
very different features of elastase (Cox 1995).
Investigation of protease-like activity may be of potential use as an indicator of tissue 
destruction since elastase is able, in vitro, to degrade some of the proteins of the 
periodontal tissues. The importance of that particular GCF protease is however difficult 
to determine. In addition, the in vivo action of elastase in GCF may not correspond to the 
in vitro action of the same amount of protease.
The alternative method, used in this study of elastase, is the direct measurement of the 
amount of elastase present, not its activity. The potential benefit of this is in 
understanding PMN dynamics in the inflammatory process. This is complicated by the 
fact that elastase exists not as an isolated enzyme but in combination with its inhibitors 
(Giannopolou et al 1992, Ohlsson and Olsson 1974).
It remains to be established whether in the gingival crevice elastase has the capacity to 
degrade connective tissue and disrupt basal lamina as has been described in vitro. 
Furthermore if it has that capacity whether the amounts that are found in GCF are 
sufficient to contribute directly to tissue damage or whether the importance of elastase 
and elastase like activity is in the disruption of other functions.
1.8.2 Lactoferrin
Lactoferrin is an iron binding protein found in the secondary granule of the PMN 
(Spitznagel et al 1974). In addition to chelating iron it is able to bind copper, but to a 
lesser extent. It is a member of the transferrin family.
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Lactoferrin is believed to function against bacteria in several ways (reviewed by Ellison 
1994); it is bacteriostatic, depriving bacteria of vital metallic growth factors (Masson & 
Hereman 1968), indirectly, by chelating metal ions it decreases the production of free 
radicals in the Haber Weiss reaction, described above (Britigan and Edeker 1991). The 
antimicrobial activity of IgG, IgM and IgA is increased in combination with lactoferrin 
(Duncan and McArthur 1981). In addition lactoferrin directly modifies the wall of Gram 
negative bacteria causing the release of LPS (Ellison 1988).
In relation to phagocytic cells and inflammation lactoferrin alters PMN adhesiveness and 
chemotaxis (Oseas et al 1981, Falloon & Gallin 1986). Britigan et al (1994) discussed the 
role of lactoferrin as an anti inflammatory agent. In addition to potentially limiting the 
production of hydroxyl radicals they suggested that lactoferrin binding of LPS altered its 
bioavailability thus reducing the inflammatory reaction.
1.9 Protease Inhibitors
The two major serum protease inhibitors, alpha 1 antitrypsin and alpha 2 macroglobulin 
are present in GCF (Ohlsson et al 1974).
1.9.1 Alpha 1 anti trypsin
Alpha 1 anti trypsin is the most abundant protease inhibitor and is present in plasma at 
concentrations of 2-4mg/ml (Heimburger 1974). It is produced principally in the liver but 
also by macrophages, monocytes and recently production in PMNs has been 
demonstrated (du Bois et al 1991).
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It has a broad range of activity against plasma proteins. Along with alpha 2 macroglobulin 
it accounts for approximately 90% of the plasma total inhibitory capacity, but is most 
active in the inhibition of serine proteinases (Ohlsson 1978). Alpha 1 antitrypsin has a 
molecular weight of 55,000. It has a 1:1 molar combining ratio with elastase which 
appears to have a higher affinity for alpha 1 antitrypsin than alpha 2  macroglobulin; 92% 
binding of elastase as opposed to 8 % with alpha 2 macroglobulin. The complex between 
alpha 1 antitrypsin and elastase possesses no residual protease activity since alpha 1 
antitrypsin binds the active site of elastase.
The half life of alpha 1 antitrypsin in the circulation is approximately 1 hour. Dissociation 
of the alpha 1 antitrypsin-elastase complex results in transfer of elastase to alpha 2  
macrdglobulin following which it is removed by cells of the reticulo-endothelial system. In 
the extra-cellular tissues the half life of these complexes is likely to be longer due to the 
much slower clearance.
1.9.2 Alpha 2 macroglobulin
Alpha 2 macroglobulin, the other principal protease inhibitor of serum, is present at 
concentrations of 1.5-4.2 mg/ml (Heimburger 1974). Like alpha 1 antitrypsin it is 
principally produced by the liver but its production in gingival macrophages has been 
demonstrated (Condacci et al 1988, Giannopoulou et al 1990). It has a molecular weight of
725,000 and is composed of 8  subunits of molecular weight 80,000 (Roberts et al 1974).
Alpha 2 macroglobulin combines irreversibly with elastase in a 2:1 molar ratio. There is no 
single binding site for elastase on alpha 2  macroglobulin, rather elastase combines with the 
central core of the molecule following its proteolytic attack of that region. This 
irreversible combination leads to a conformational change in the alpha 2  macroglobulin
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which is subsequently treated as a foreign body and eliminated by monocytes. The alpha 
2  macroglobulin/elastase complex retains limited proteolytic activity against low molecular 
weight proteins (Barrett and Starkey 1974, James 1980).
The interaction of protease with alpha 2 macroglobulin has certain characteristics (Barrett 
and Starkey 1974):
• Only active endopeptidases react
• The enzyme is irreversibly bound
• A molecule of alpha 2 macroglobulin can react with only one molecule of protease.
• Bound enzyme is most inhibited with respect to large substrate molecules
• Bound enzyme is protected from other high molecular weight inhibitors
Alpha 2 macroglobulin has several important functions in the immune system. In vitro it 
binds not only to active proteases but also lymphokines. The possible role of alpha 2 
macroglobulin in the immune system was reviewed by James (1980). Briefly, in vitro 
evidence suggests that it may be synthesised by lymphocytes, that it can alter the 
response of lymphoreticular cells to chemotactic and mitogenic agents thereby potentially 
affecting the recruitment and activation of macrophages and PMNs at inflammatory sites.
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1.10 Aim of Study
The aim of the study was to examine the dynamics of degranulation of PMNs in the gingival 
crevice. It was postulated that an alteration in PMN degranulation dynamics may be useful 
as a marker of inflammatory periodontal disease rather than simple gingival inflammation. It 
was further postulated that the function and activity of elastase is locally altered by the 
presence of its inhibitors. This functional alteration may be indicated by a change in the 
relative levels of elastase and its inhibitors at different categories of sites.
GCF was collected from healthy, gingivitis and periodontitis sites within the same 
individual for the study. The. PMN granule components elastase and lactoferrin, primary 
and secondary granule markers respectively, were identified in GCF. In addition the 
relationship of elastase to alpha 1 anti trypsin and alpha 2  macroglobulin, its principal 
inhibitors, at the same sites was measured. It was felt that by collecting GCF from different 
sites in the same individual some of the inter individual variability would be avoided.
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CHAPTER 2
Clinical and Experimental Materials and Methods
Clinical Methods
2.1 Study Design
The study was cross sectional with 10 individuals examined and included for data and 
sample collection. Ethical committee approval was obtained for the study prior to its 
commencement. All individuals gave informed consent prior to their inclusion in the 
study. At the time of its inception the study was unique in the examination of PMN 
markers from different quality periodontal sites in the same individual.
2.2 Subject and site selection
Newly referred patients attending the Periodontal Department of Glasgow Dental 
Hospital and School were screened for inclusion in the study at their initial consultation 
visit.
All individuals were over 18 years of age and had clear medical histories with reference to 
conditions or treatments likely to alter the presentation or course of periodontal diseases. 
All were questioned regarding tobacco usage and were excluded if they admitted to its use. 
In addition to these systemic features, patients who had undergone periodontal treatments 
or used antibiotics in the previous 3 months were excluded. This was done in an attempt 
to avoid the effect of instrumentation and disruption on the periodontal environment 
when samples were collected.
All patients underwent a periodontal examination at which time 3 sites were identified for 
the collection of GCF. These sites required to be easily accessible and capable of isolation
34
from salivary contamination. The sites identified were classed according to gingival 
condition, probing depth and radiographic examination as:
Healthy sites with no evidence of periodontal attachment loss, no bleeding
on probing, no marginal gingivitis and periodontal pocketing of 
<3 mm.
Gingivitis no evidence of periodontal attachment loss, periodontal pocketing
<3mm, bleeding on probing and marginal gingivitis.
Periodontitis evidence of periodontal attachment loss as assessed clinically and
radiographically, periodontal pocketing of >4mm, bleeding on 
................................. probing and marginal gingivitis..............................................................
Following the identification of sites, arrangements were made to see the patients on a 
subsequent visit, prior to their first treatment session, for the collection of data and 
samples.
2.3 Clinical Measurements of Periodontal Status
An index is an objective method for measuring a clinical state. The use of an index facilitates 
the standardization of the degree of change or difference in the condition under observation. 
The choice of one index in preference to another depends on the aims and objectives of the 
situation and has been discussed extensively (Mandel 1974).
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2.3.1 Plaque Indices
In the measurement of plaque and soft accumulations on teeth and restorations, indices 
estimate either the extent of tooth coverage or the thickness of deposits in relation to the 
gingival margin (Fischman 1986).
If the objective is to determine the efficacy of plaque removal or inhibition measures, then 
the measurement of changes in the area of tooth coverage may be desirable. If the objective 
in recording an index is to examine the relationship of plaque to the gingival condition, then 
it is more appropriate to employ an index system which weights the quantity of plaque at 
the gingival m arg in ,.................................................................................................................
For the purposes of the present study the Plaque Index of Silness and Loe (Loe 1967) 
was used since it relates plaque deposits to the gingival tissues on the following scale:
0  no plaque present at the gingival area either visually or with a probe run along the 
tooth surface.
1 plaque present in a thin film at the gingival margin adherent to the tooth. This is 
not detected visually but by running a probe along the gingival area of the tooth 
surface.
2 Moderate accumulations of plaque and soft deposits in the gingival area, which can 
be seen with the naked eye.
3 Large accumulations of plaque and soft deposits in the gingival area, visible with 
the naked eye.
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One criticism of this index is that it is not particularly sensitive to small variations in 
plaque levels. As the present study aimed principally to differentiate sites on the basis of 
gingival inflammation rather than plaque accumulation this was not considered to be of 
major importance.
2.3.2 Gingival Indices
As with indices of plaque, there are several techniques for observing the degree of gingivitis. 
As with plaque indices the selection of an appropriate index depends on the aims and 
objectives of the particular study.
The available indices rely on observations relating to gingival colour, gingival contour, 
bleeding on probing, the extent of gingival involvement or gingival crevicular fluid flow 
(Cianco 1986). They can be divided into those which report visual changes in the gingival 
tissue and those which rely not only on visual changes but also on the presence or absence 
of bleeding on probing in the gingival crevice or interdental region.
The recording of many indices causes disruption of the gingival crevice due to the 
insertion of a periodontal probe into it (reviewed by Ciancio 1986, Lobene et al 1986). 
This has 2 major effects; firstly if more than one examiner is involved in the collection of 
data trauma caused by the initial examiner can distort the site for subsequent examiners, 
secondly, the gingival crevice itself will be disrupted, most often by bleeding or the 
disturbance of subgingival plaque during recording. This has implications for the collection 
of GCF from that region with regard to the contamination of samples with blood or 
inaccurate microbiological samples.
37
The major clinical component of the present study involved the collection of samples of 
GCF. Care was taken in the selection of patients who had undergone no recent 
periodontal interventions and thus had undisturbed gingival crevices. The gingival index of 
Lobene et al (1986) is an index sensitive to small visual changes in gingival quality and it 
does not involve periodontal probing. This index had been used successfully in the 
department in previous studies (Adonogianaki 1992, Haerian et al 1995) where 
uncontaminated samples of GCF were required. The following scale is used:
0  no inflammation
1 mild inflammation; slight changes in colour, little changes in a portion of the 
gingival tissue but not involving the entire marginal or papillary unit.
2  mild inflammation as above but involving the entire gingival or papillary unit
3 moderate inflammation; glazing, redness, oedema and/or hypertrophy of the 
marginal gingival or papillary unit
4 severe inflammation; marked redness, oedema and/or hypertrophy of the marginal 
or papillary gingival unit, spontaneous bleeding, congestion or ulceration.
2.3.3 Periodontal Probing
Periodontal probing is an established and widely used method for the assessment of 
periodontal status (Greenstein 1984, Lang et al 1990). It involves the insertion of a 
calibrated probe into the gingival sulcus or periodontal pocket, parallel to the long axis of the 
tooth root, to the point of resistance. A measurement of that depth either with reference to 
the gingival margin, the amelo-cemental junction or to a fixed point on the tooth or 
measuring stent is then made. The principal clinical limitation of periodontal probing is its 
ability to monitor tissue changes only retrospectively (Caton et al 1981, Listgarten 1980).
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In cross sectional trials there is no requirement for reproducibility of probing depth at 
separated time points, despite this a reliable and reproducible probing technique is required. 
When clinical groupings are widely separated in terms of pocket depth the sensitivity of the 
technique to fractions of millimeters is not critical. In the present study the presence or 
absence of disease was based on a combination of clinical features. Site discrimination was 
on the basis of probing depth, attachment loss and the degree of superficial inflammation.
Probing depths were measured in millimetres using a calibrated Williams probe. The probe 
was inserted into the pocket in the long axis of the tooth until resistance was felt. The 
pocket depth was read visually and recorded.
2.3.4 Collection of GCF
Samples were collected using Whatmann grade 4 paper. Strips of 2mm by 13mm were cut 
and marked at a distance of 8 mm from the end then autoclaved. This mark was an 
indication of the length of paper to be inserted between the beaks of the Periotron. All 
strips were handled using rubber gloves to avoid contamination by the operator and were 
stored in sterile glass bottles prior to use.
As previously discussed, Griffiths et al (1988) suggested that Whatmann grade 3 papers 
had the ideal properties for collection of GCF, however, previous experience in the 
department (Adonogianaki 1992) showed that zero readings could not be obtained on the 
Periotron with that paper.
The selected sites were isolated using a saliva ejector and cotton wool rolls to avoid 
contamination. Supragingival plaque was removed atraumatically using a curette. The site 
was dried using a gentle, coronally directed stream of air. Following this a paper strip was
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inserted into the pocket orifice until light resistance was felt. The strip was left in situ for 
30 seconds. Any strip visibly contaminated by blood was discarded and if the patient did 
not have an alternative, previously identified, site for sampling they were excluded from 
the trial. After removal from the sulcus, the strip was immediately placed between the 
beaks of the Periotron and the volume reading recorded. The strip was placed in a 
microcentrifuge tube, sealed to avoid evaporation and stored on ice prior to transfer to the 
lab for elution.
2.4 Sequence of collection
Samples and data were collected in the following sequence:
1. Plaque Index
2. Gingival Index
3. GCF collection
4. GCF volume determination
5. Probing pocket depth
All recordings and samples were obtained by one operator (M.C Murray) who had been 
previously calibrated in the recording of the indices and the collection of GCF as 
described.
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Experimental Materials and Methods
2.5 Buffers
All chemicals, unless otherwise stated, used for the preparation of buffers were supplied 
by BDH Laboratory Supplies, Poole, Dorset.
2.5.1 Phosphate Buffered Saline
PBS used throughout the experiments had the following composition:
8 g NaCl
1.44g Na2 HP0 4 .2H20
0.2g KH2P04
0.2g KC1
made up to 1 litre with distilled H20
2.5.2 Coating Buffer
Coating buffer was used for the carriage of reagents and samples in the coating phases of 
the experiments and in the pre-coating wash stage:
1.5g Na2 CC>3
2.93g NaHC03
dissolved in 800ml of distilled water.
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This solution was made up to almost 1 litre with distilled water and the pH corrected to 
9.6. Distilled water was then added to give a final volume of 1 litre. Coating buffer was 
stored at 4°C for a maximum of 1 week prior to use.
2.5.3 Incubation Buffer
The following incubation buffer was used as the carrier for all experiments during the 
incubation phase:
8 g NaCl
1.44g Na2 HP0 4 .2H20
0 .2 g KH2 P 0 4
0.2g KC1
0.5g Tween 20 (Sigma Chemical Company, Poole, Dorset)
This was made up to 1 litre in distilled H20.
lg of BSA (Sigma, St Louis, USA) was layered over the surface and allowed to dissolve. 
The buffer was stored at 4°C for a maximum of 1 week prior to use.
2.5.4 Wash Buffer
Wash buffer was used between the different stages of incubation to remove the unbound 
antibody or antigen from the wells:
80g NaCl
14.4g Na2 HP0 4 .2H20
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2g KH2P04
2g Kcl
5g Tween 20 (Sigma Chemical Company, Poole, Dorset)
Dissolved in 1 litre of distilled water. This was stored at room temperature and diluted 1 
in 1 0  immediately prior to use with distilled water.
2.5.5 Substrate Buffer
For the final visualisation of the reaction in the wells, substrate buffer was used:
0.3 5g Na2 HP0 4
0.2375g Citric acid
this was dissolved in 25ml of distilled water and subsequently
lOmg (1 tablet) O-phenylenediamide dihydrochloride(OPD) (Sigma Immuno
Chemicals, St Louis, USA)
lOul H2 0 2
were added. This substrate was prepared in a fume cupboard immediately prior to use as 
OPD is toxic and the buffer unstable.
2.5.6 H2S 0 4
H2 S0 4  was used to stop the reaction of the substrate buffer on all occasions. This was 
prepared in the fume cupboard to give a solution with a final concentration of 1 M
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2.6 Periotron
2.6.1 Calibration of the Periotron
The Periotron 6000 GCF was used (Harco Electronics, Winnipeg, Canada). Calibration of 
the Periotron was undertaken as described by Adonogianaki (1992). Briefly, the Periotron 
was calibrated at every clinical session with PBS to take into account the effect of changes 
in atmospheric humidity. Known volumes of PBS were delivered onto Whatmann grade 4 
paper strips, identical to those used for sample collection, using a Hamilton syringe. 
Volumes between 0.1 and 0.9ml were used in duplicate. Mean values of these recordings 
were used in a linear regression analysis from which the slope and intercept were used to 
determine GCF volumes using a Quattro software package.
2.7 Elution of samples
Samples were eluted into 1 ml of incubation buffer within 1 hour of collection. This was 
carried out over 1 hour at room temperature on a rotating mixer. Following this initial 
elution the sample was divided into 200ul aliquots and stored at -30°C in microcentrifuge 
tubes until use in the ELISA.
A standard elution technique was used. It was not possible to divide the elutions between 
coating and incubation buffers. This was not ideal with regard to the elastase assay where 
the samples were being used at the initial coating stage.
Sample dilution prior to capture on the plate was carried out to ensure values which fell 
within the working range of the assay as described. This sample dilution allowed for the
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quantification of all substances from aliquots of the same sample. The dilutions were 
carried out as indicated on table 2 .1 .
2.8 Quantification of lactoferrin, alpha 1 anti trypsin, alpha 2 macroglobulin 
and elastase
2.8.1 Plates
All of the ELISA experiments were carried out using 96 well, Immulon 4 microtiter plates 
(Dynatech Laboratories, Virginia, USA). These plastic plates are formulated to give high 
protein absorption and binding, with low well-to-well variation.
These plates had been used and validated previously within the department for the ELISA 
tests being carried out.
2.8.2 Lactoferrin, alpha 1 antitrypsin and alpha 2 macroglobulin ELISAs
These were as described by Adonogianaki (1992) and are outlined on table 2.2
All were sandwich ELISAs using primary and secondary antibodies for the capture and 
identification respectively of the agent under investigation in GCF sample.
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Table 2.1 GCF sample dilutions after elution from strips and prior to use in 
the ELISA
Assay
GCF Volume (v) in 
uL
alpha 2 macroglobulin alpha 1 antitrypsin and 
lactoferrin
Dilution factor
elastase
v <- 0.1 1/2.5 1/5 undiluted
0.1 < v <- 0.2 1 /5 1 / 1 0 undiluted
0.2 < v <- 0.4 1 / 1 0 1 / 2 0 undiluted
0.4 < v <- 0.8 1 / 2 0 1/40 undiluted
0.8 < v 1/40 1/80 undiluted
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Table 2.2 Steps and reagents for lactoferrin, alpha 2 macroglobulin and alpha 
1 antitrypsin ELISAs
STEPS REAGENTS
1. Wash with 200uL/well three times, CB and dry
2. Coat with lOOuL/well specific antiserum. Goat antisera to: lactoferrin and alpha
Incubate overnight at 4°C 2 macroglobulin 1:6000 in CB; alpha 1
antitrypsin 1:3000 in CB
3. Wash with 200uL/well WB 6  times/well, 3
times and dry
4. Add 1 OOuL/well standard antigen or eluted Standard lactoferrin, alpha 2
. . sample. Incubate for 2 hours 3 7°C macroglobulin or alpha 1 antitrypsin in
IB
5. Wash with 200uL/well WB 6  times/well, 3
times and dry
6 . Incubate with lOOuL/well second specific Rabbit antisera to: lactoferrin, alpha 2
antiserum overnight, 4°C macroglobulin or alpha 1 antitrypsin
1:4000 in IB
7. Wash 200uL/well WB 6  times/well, 3 times
and dry
8 . Add lOOuL/well HRP conjugated IgG. Incubate HRP anti rabbit IgG(goat), 1:4000 in
at 37°C for 90 mins IB
9. Wash with 200uL/well WB 6  times/well, 3
times and dry
10.Add lOOuL/well substrate buffer and incubate
at room temp (alpha 1 antitrypsin and alpha 2
macroglobulin J 5  mins, lactoferrin ^ 20 mins.
11. Stop colour development with the addition of
H2 SO4  1M, 50uL/well. Read at 490nm.
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Alpha 2 macroglobulin, Goat anti alpha macroglobulin, rabbit anti alpha 2 macroglobulin, 
alpha 1 antitrypsin, goat anti alpha 1 antitrypsin and rabbit anti alpha 1 anti trypsin were 
all supplied by Sigma Immuno Chemicals (St Louis, USA). Lactoferrin was supplied by 
Calbiochem. Goat anti lactoferrin and rabbit anti lactoferrin were supplied by Nordic. 
HRP conjugated anti rabbit IgG was supplied by ICN. OPD was supplied by Sigma (St 
Louis, USA).
Sample dilution prior to capture on the plate was carried out to ensure values which fell 
within the working range of the assay as described. The working ranges of the assays are 
displayed in Table 2.3.
The recovery rate of the 3 agents had been previously determined and was as shown in 
Table 2.4.
All plates had peripheral control wells and incorporated serial dilutions of pure agent in 
duplicate. The mean of the readings for these dilutions was used in a regression analysis 
the slope and intercept of which was used for the conversion of plate readings to the 
amount of agent in the sample. Wells at the edge of the plate were not used for sample 
quantification to avoid the edge effect (Tijssen 1988)
2.8.3 Elastase ELISA
An ELISA was devised for the detection and quantification of PMN elastase. Due to the 
difficulties in obtaining an anti PMN elastase antibody and the difficulty of working with 
a biotinylated polyclonal PMN elastase antibody, a direct ELISA was used, table 2.5. 
Purified PMN elastase was supplied by Sigma. Rabbit anti PMN elastase was supplied 
by Calbiochem, (La Jolla, CA). HRP conjugated anti rabbit IgG was supplied by ICN.
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Table 2.3 Working range of the standard antigen for the ELISA assays of
elastase, lactoferrin, alpha 1 antitrypsin and alpha 2 macroglobulin.
Assay Working range ng/mL
Elastase 125 - 0.24
Lactoferrin 125 - 0.24
Alpha 1 antitrypsin 100-0.19
Alpha 2 macroglobulin 200 -0.39
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Table 2.4 Recovery rates of alpha 2 macroglobulin, alpha 1 antitrypsin and
lactoferrin in incubation buffer (IB). (From : Adonogianaki 1992)
Concentration in 
lmL of eluate 
ng/mL
Recovery rate
Analyte strip (n=7) IB (n=3)
Alpha 2 
macroglobulin
1520+/-52 1527+/- 53 99.5%
Alpha 1 antitrypsin 1266 +/- 72 1273 +/-41 99.4%
Lactoferrin 3763 +/- 232 4509 +/- 81 83.4%
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As part of the study the recovery rate of elastase was determined. As samples had all 
been eluted into incubation buffer, comparisons were made between the recovery rate 
from incubation and coating buffers. Purified PMN elastase standard was used.
The following procedure was carried out; lul of stock purified PMN elastase at lmg/mL 
was delivered into one of the following:
• on Whatman Grade 4 paper strips, 10 strips, subsequently eluted into 1ml of either 
incubation buffer (n=5) or coating buffer (n=5) at 22°C on a rotating mixer for 1 hour
• directly (n=10) either into 1ml of incubation buffer (n=5) or coating buffer (n=5) and 
rotated at 22°C on a rotating mixer for 1 hour
Delivering pure PMN elastase into both incubation and coating buffers enabled the 
determination of the reduction in coating which would be found using GCF samples in the 
assay. Following elution as described above, the samples were coated onto plates and the 
ELISA run as outlined in Table 2.5. The recovery rate of elastase from incubation buffer 
was greatly reduced, see Table 2.6, but was still well within the working range of the 
assay. Clinical samples used in the elastase ELISA were not diluted following initial 
elution prior to use in the assay due to this low recovery rate.
As with the ELISAs for lactoferrin, alpha 1 antitrypsin and alpha 2 macroglobulin, each 
plate incorporated peripheral control wells and serial dilutions of pure agent in duplicate. 
The mean of the duplicate measurements was used in a regression analysis the slope and 
intercept of which was used for the conversion of plate readings to the amount of agent in 
the sample.
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Table 2.5 Steps and reagents for the elastase ELISA
STEPS
1. Wash with CB 200uL/well 6 times/well, three times and dry
2. Standard elastase in CB or eluted GCF sample added and incubated overnight at 4°C.
3. Wash with WB 200uL/well 6 times/well, three times and dry
4. Add Rabbit anti elastase at 1 in 1000 dilution in IB, incubate at 37°C for 2 hours
5. Wash with WB 200uL/well 6 times/well, three times and dry
6. Add HRP anti rabbit IgG at 1 in 10000 dilution in IB. Incubate at 37°C for 11/2 hours.
7. Wash with WB 200uL/well 6 times/well, three times and dry
8. Add OPD substrate lOOuL/well, incubate for ~15mins at room temperature.
9. Reaction stopped by the addition of 50uL/well of H2S04
The reaction was finally read at 490nm using a Dynatech MR 5000 plate reader
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Table 2.6 : Recovery rate of elastase from coating buffer and incubation buffer
compared with elution directly into coating buffer
Method of delivery Average concentration 
(ng/mL)
Percentage recovery 
rate
Direct to incubation buffer 1.2088 2.6%
Strip to coating buffer 0.8022 1.7%
Strip to incubation buffer 1.253 2.7%
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2.9 Statistical analysis
Statistical analysis was carried out using a Minitab release 9.2 package.
For all analysis the site was taken as the statistical unit. Data referring to alpha 1 
antitrypsin, alpha 2 macroglobulin, lactoferrin and elastase were markedly skewed in their 
distribution. As a result, analysis was carried out on the log transformed data relating to 
all of the biochemical parameters with the exception of elastase. For elastase, even 
following transformation, the distribution was not normal and as a result non parametric 
tests were carried out in relation to this.
Since three comparisons were being made between the groups when using the 2 sample t 
test, the level of significance was taken as 0.025, thus compensating for the 3 comparisons 
(Brown and Swanson Beck, 1988)
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CHAPTER 3
RESULTS
3.1 Clinical study
3.1.1 Sample Description
A total of 10 subjects were recruited to the study, 3 males and 7 females, age range 37-51 
years. Each subject had GCF samples collected in a standardised way, as described in 
Chapter 2, from all 3 categories of sites i.e. healthy, gingivitis and periodontitis.
3.1.2 Plaque Index
The mean plaque index at healthy sites was 0.1 (range 0-1, SD 0.316), at gingivitis sites 
0.9 (range 0-3, SD 1.101) and at periodontitis sites 1.7 (range 0-3, SD 0.823).
Using the 2 sample t test the healthy group showed a statistically significant difference 
from the periodontitis group, p<0.0001. Differences between healthy and gingivitis sites, 
p=0.052, and gingivitis and periodontitis sites, p=0.084, were not significant.
3.1.3 Gingival Index
The mean gingival index at healthy sites was 0.1 (range 0-1, SD 0.316), at gingivitis sites
2.4 (range 1-3, SD 0.699) and at periodontitis sites 2.3 (range 1-3, SD 0.823)
Using the 2 sample t test significant differences were shown between healthy and 
gingivitis sites, p<0.001, between healthy and periodontitis sites, p<0.001 but not 
between gingivitis and periodontitis sites, p=0.77.
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This finding confirmed the clinically observed separation between healthy and inflamed 
sites in either gingivitis or periodontitis categories on the basis of the modified gingival 
index. In addition, the level of superficial inflammation as judged clinically, was similar in 
gingivitis and periodontitis sites.
3.1.4 Pocket Depth
The mean pocket depth at healthy sites was 0.9mm (range 0-2, SD 0.699), at gingivitis 
sites 2.6mm (range 2-3mm, SD 0.516) and at periodontitis sites 5.8mm (range 4-10mm, 
SD 1.1814).
Using the 2 sample t test, significant differences were found between all groups; healthy 
compared with gingivitis p<0.001, healthy compared with periodontitis p<0.001 and 
gingivitis compared with periodontitis p=0.003.
The clinical groups showed almost complete separation, again confirming the clinical 
differences between the groups.
3.1.5 Gingival Crevicular Fluid Volume
The mean GCF collected over 30 seconds at healthy sites was 0.1014ul (range 0.005- 
0.618, SD 0.1821), at gingivitis sites 0.1474ul (range 0.014-0.331, SD 0.0999) and at 
periodontitis sites 0.4213 (range 0.005-0.7530, SD 0.2204).
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Data for GCF volume were markedly skewed. Log transformation produced a normal 
distribution and thus satisfied the distributional requirements of the 2 sample t test. 
Despite the tendency for GCF volume to increase from healthy to gingivitis sites this was 
not significant, p=0.13. Between healthy and periodontitis sites a significant difference 
was present, p=0.0099, but was absent when gingivitis and periodontitis sites were 
compared, p=0.11.
These data confirmed the tendency for GCF volume to be increased at sites with 
inflammation and increased pocket depth.
The above, clinical results, particularly -relating to pocket depth and gingival inflammation, 
confirm that the separation and selection on clinical grounds at entry into the study was 
valid. In addition to the measurement of superficial gingival inflammation, using the 
modified gingival index and pocket depth, all sites in both the gingivitis and periodontitis 
groups exhibited bleeding on probing into the gingival crevice. Inclusion of this feature 
reduces the possibility that a non active site is chosen for sampling (Lang et al 1990).
3.2 PMN Granule Markers
3.2.1 Elastase (Primary PMN granule)
As the distribution of values relating to elastase could not be normalised following log 
transformation, analysis was carried out using the non parametric Mann Whitney test.
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Absolute Amounts (ng/30 second sample)
The mean amount of elastase detected at healthy sites was 0.475ng (range 0-1.1216ng, SD 
0.427), at gingivitis 1.56ng (range 0-11.6ng, SD 3.35) and at periodontitis sites 0.363ng 
(range 0.1198-0.8462, SD 0.2558).
Although there was a slight tendency for elastase levels to be higher at gingivitis sites 
compared with healthy, p=0.497, and at periodontitis sites, p=0.1859 compared with 
healthy, this was not significant. In addition gingivitis and periodontitis sites could not be 
discriminated on the basis of the amount of elastase, p=0.7333.
Concentration (ng/ul/30 second sample)
The mean concentration of elastase at healthy sites was 12.59ng (range 0-57.1, SD 17.2), 
at gingivitis sites 9.57ng (range 0-53.7, SD 16.04) and at periodontitis sites 3.35ng (range 
0.26-23.95, SD 7.34).
Again, no significant differences were found between healthy and gingivitis sites, 
p=0.7055 or healthy and periodontitis sites, p=0.3447. The difference between gingivitis 
and periodontitis sites just failed to reach significance, p=0.0452. Gingivitis sites had 
higher mean concentration than periodontitis.
For all the sampled groups the range of values for both absolute amounts and concentration 
of elastase was very wide with large standard deviations being present. This may explain 
why no statistically significant differences could be detected between the different types of 
site. Larger numbers of subjects would be required to confirm whether the absence
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of any difference was due to the small sample size or was in fact a biological feature.
3.2.2 Lactoferrin (Secondary PMN granule)
Absolute amounts (ng/30 second sample)
The mean amount of lactoferrin detected at healthy sites was 106ng (range 2.3-649, SD 
193.9), at gingivitis sites 87 (range 22.7-288, SD 77.8) and at periodontitis sites 620 
(range 3-1518, SD 538).
Statistically significant differences were present using the 2 sample t test, between 
healthy and periodontitis sites, p=0.0021, but not between healthy and gingivitis, p=0.31, 
or gingivitis and periodontitis sites, p=0.052.
Concentration (ng/ul/30 second sample)
The mean concentration of lactoferrin detected at healthy sites was 2288ng (range 47- 
14782, SD 4446), at gingivitis sites 804 (range 208-2217, SD 626) and at periodontitis 
sites 2368 (range 7-11633, SD 3354).
No significant differences were present between any of the groups in relation to 
lactoferrin concentrations using the 2 sample t test; healthy compared with gingivitis 
p=0.79, healthy compared with periodontitis p=0.71 and gingivitis compared with 
periodontitis p=0.49.
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Figure 3.2: Absolute amount of lactoferrin/30 second GCF sample
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These data confirm previous findings in our laboratory that the amount of lactoferrin 
recovered in GCF is related to the GCF volume and that the concentration remains 
constant at different disease levels.
3.2.3 Relationship of Elastase to Lactoferrin as an indicator of Primary and 
Secondary PMN granule release
The relationship of primary and secondary granule products at all categories of disease 
sites was examined. This data was not normally distributed and could not be normalised 
following log transformation, thus the non-parametric Mann Whitney test was used in the 
analysis of the raw data.
The mean lactoferrin to elastase ratio at healthy sites was 133.3 (range 2.3-533, SD 165), 
at gingivitis sites 136.8 (range 7.7-272.1, SD 102.7) and at periodontitis sites 1973 (range 
13-4140, SD 1485).
No significant differences were found between healthy and gingivitis sites, p=0.4274. 
However between gingivitis and periodontitis, p=0.0073 and between healthy and 
periodontitis sites, p=0.0058, highly significant differences were present with a 10 fold 
increase in the amounts of lactoferrin relative to elastase present in the samples.
This difference in the relationship of elastase to lactoferrin may be an indicator of altered 
PMN granule release dynamics at periodontitis sites and may be a useful discriminator 
between gingivitis and periodontitis.
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3.3 Protease Inhibitors
3.3.1 Alpha 1 anti trypsin
Absolute amounts (ng/30 second sample)
At healthy sites the mean amount of alpha 1 anti trypsin detected was 112.5ng (range 1.7- 
369.3, SD 138.3), at gingivitis sites 485ng (range 146-1410, SD 403) and at periodontitis 
sites 707 (range 97-1482, SD 448).
An increase in the amount of alpha 1 anti trypsin detected was seen from healthy through 
gingivitis to periodontitis sites. The 2 sample t test showed significant differences 
between healthy and gingivitis sites, p=0.0033, and between healthy and periodontitis 
sites, p=0.0009 but not between gingivitis and periodontitis sites, p=0.26
Concentrations (ng/ul/30 second sample)
The mean concentration of alpha 1 anti trypsin at healthy sites was 2615 (range 35- 
10176, SD 3616), at gingivitis sites 4993 (range 941-20774, SD 5766) and at periodontitis 
sites 3469 (range 678-19362, SD 5639).
Using the 2 sample t test no significant differences were found between healthy and 
gingivitis sites, p=0.053, healthy and periodontitis sites, p=0.25 and gingivitis and 
periodontitis sites, p=0.19. Again however, there was a tendency for the concentration of
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alpha 1 anti trypsin to be greater at gingivitis sites than at either healthy or periodontitis 
sites.
3.3.2 Alpha 2 macroglobulin 
Absolute amounts (ng/30 second sample)
The mean amount of alpha 2 macroglobulin detected at healthy sites was 46.4ng (range 
3.3-181.5, SD 56.3), at gingivitis sites 594 (range 49-1958, SD 595) and at periodontitis 
sites 636 (range 31-3508, SD 1041) A sharp increase in the amount of inhibitor present at 
gingivitis and periodontitis sites was seen.
The 2 sample t test showed significant differences between healthy and gingivitis sites, 
p=0.0001 and between healthy and periodontitis sites, p=0.0008 but not between 
gingivitis and periodontitis sites, p=0.66.
Concentration (ng/ul/30 second sample)
The mean concentration of alpha 2 macroglobulin at healthy sites was 1076 (range 66- 
4935, SD 1531), at gingivitis sites 10961 (range 279-75783, SD 23071) and at 
periodontitis sites 2163 (range 110-9040, SD 3010).
Increased concentrations of inhibitor were present at gingivitis sites.
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The 2 sample t test showed significant differences between healthy and gingivitis sites, 
p=0.0084 and a tendency to a difference between gingivitis and periodontitis sites, 
p=0.076 but no difference between healthy and periodontitis sites, p=0.25.
3.3.3 Relationship of alpha 1 anti trypsin and alpha 2 macroglobulin
The relationship of alpha 1 anti trypsin to alpha 2 macroglobulin was calculated for each 
site to determine if any change occurred in the relative amounts of these inhibitors at 
different types of sites.
Again, the data were skewed but had a normal distribution following log transformation. 
Thus, log transformed data were used in parametric analysis.
At healthy sites the mean alpha 1 anti trypsin/alpha 2 macroglobulin ratio was 2.61 (range 
0.526-5.758, SD 1.676), at gingivitis sites 1.264 (range 0.274-3.41, SD 0.909) and at 
periodontitis sites 3.16 (range 0.37-12.65, SD 3.63).
Although there was a tendency for the amount of alpha 1 anti trypsin relative to alpha 2 
macroglobulin to be higher at healthy sites, p=0.055 and periodontitis sites, p=0.090, than 
at gingivitis sites; no difference was detected between healthy and periodontitis sites, 
p=0.98.
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3.4 Relationship of elastase to its inhibitors
In an attempt to display potential differences between the relative levels of inhibitors and 
elastase at different disease sites, the ratio between elastase and its inhibitors was 
calculated for each site.
As the data were skewed, and following log transformation did not assume a normal 
distribution, the non parametric Mann Whitney test was used in the analysis.
3.4.1 Alpha 1 anti trypsin/Elastase
At healthy sites the mean alpha 1 anti trypsin/elastase ratio was 179.2 (range 1.7-874, SD 
261.3), at gingivitis sites 728 (range 33-1583, SD 565) and at periodontitis sites 2464 
(range 574-6578, SD 565).
There was a marked increase in the amount of inhibitor present relative to elastase from 
healthy through to periodontitis sites. Significant differences were detected between 
healthy and gingivits sites, p=0.0091, healthy and periodontitis sites, p=0.0003 and 
gingivitis and periodontitis sites, p=0.0028.
Alpha 1 anti trypsin binds elastase and completely inhibits its proteolytic ability. The 
finding that there is a relative increase in the amount of alpha 1 anti trypsin at sites of 
inflammation and attachment loss tends to support an attempt by the host to protect the 
tissues from the effects of elastase and potential tissue degradation.
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3.4.2 Alpha 2 macroglobulin/Elastase
The mean ratio of alpha 2 macroglobulin/elastase at healthy sites was 72.4 (range 3.3-263, 
SD 82.5), at gingivitis sites 858 (range 14-2090, SD 708) and at periodontitis sites 2829 
(range 90-17547, SD 5301).
Again, there was a large increase in the amount of inhibitor relative to elastase from 
healthy through to periodontitis sites. Significant differences were present between 
healthy and gingivitis sites, p=0.0028, and healthy and periodontitis sites, p=0.0008, but 
not between gingivitis and periodontitis sites, p=0.4274.
Alpha 2 macroglobulin binds elastase and inhibits some, but not all, of its protease 
activity. Again, a relative increase in the amount of the inhibitor at sites of inflammation 
would support an attempt by the host to protect the tissues. However, unlike alpha 1 
anti trypsin where the relative amount increases from gingivitis to periodontitis, this is 
not seen for alpha 2 macroglobulin. This is confirmed below when the correlation between 
alpha 2 macroglobulin and elastase is seen to be lower than between alpha 1 anti trypsin 
and elastase.
3.5 Correlations between clinical and biochemical parameters
The correlations between the various clinical and biochemical parameters used in the 
study were examined. Only that data which was continuous was used in the correlation. 
Because of the skewed distribution of the data, values relating to alpha 1 anti trypsin, 
alpha 2 macroglobulin, elastase, lactoferrin and GCF volume were all log transformed. 
Where pocket depth was included in the correlation it was non transformed. The 
correlation analysis was carried out on stacked data.
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Correlations were found between :
Alpha 1 anti trypsin with alpha 2 macroglobulin r=0.861 
Alpha 1 anti trypsin with elastase, r=0.582 
Alpha 1 anti trypsin with lactoferrin, r=0.572 
Alpha 1 anti trypsin with GCF volume, r=0.636 
Alpha 1 anti trypsin with pocket depth, r=0.610 
Alpha 2 macroglobulin with GCF volume, r=0.454 
Alpha 2 macroglobulin with pocket depth, r=0.430 
Lactoferrin with GCF volume, r=0.697 
Lactoferrin with pocket depth, r=0.626 
GCF volume with pocket depth, r=0.708
Other correlations which were present were of r less than 0.4 and as a result were not 
reported.
If the desired level of correlation is set as that established between GCF volume and 
pocket depth, then the correlation between alpha 1 anti trypsin and alpha 2 macroglobulin 
is extremely high. It is considered that these inhibitors, although principally produced in 
the liver and derived in GCF from serum, are locally produced at sites of inflammation. 
The correlation would suggest that the local production of the two inhibitors is not 
completely, if at all, mutually independent.
Another interesting finding is of the poorer correlation between elastase and alpha 2 
macroglobulin, r=0.377, than between elastase and alpha 1 anti trypsin, r=0.582. Given 
the fact that in our samples the relative amounts of alpha 1 anti trypsin and elastase, but
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not alpha 2 macroglobulin and elastase at a site could distinguish not only between 
healthy and gingivitis sites or healthy and periodontitis sites but also between 
periodontitis and gingivitis sites, this combination of elastase and alpha 1 anti trypsin 
may be the one which is of more importance in disease differentiation than that of elastase 
and alpha 2 macroglobulin.
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Table 3.1 : Clinical Characteristics of sampled sites (mean and standard deviation)
Parameter Healthy Gingivitis Periodontitis
Gingival crevicular 
fluid volume (uL)
0.1014 sd 0.1821 0.1474 sd 0.0999 0.4213 sd 0.2204
Plaque Index 0.100 sd 0.316 0.900 sd 1.101 1.700 sd 0.823
Gingival Index 0.100 sd 0.316 2.400 sd 0.699 2.300 sd 0.823
Probing
Depth(mm)
0.900 sd 0.699 2.600 sd 0.516 5.800 sd 1.814
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Table 3.2: PMN granule components (mean and standard deviation)
Parameter Healthy Gingivitis Periodontitis
Elastase
(ng/30s)
0.3500 sd 0.2903 0.598 sd 0.695 0.2947 sd 0.1797
Elastase
(ng/uL/30s)
64.0 sd 178.3 10.05 sd 15.85 3.35 sd 7.33
Lactoferrin
(ng/30s)
3.671 sd 1.528 4.213 sd 0.738 5.654 sd 1.847
Lactoferrin
(ng/uL/30s)
2333 sd 4447 778 sd 649 2368 sd 3353
Lactoferrin/ 
Elastase ratio
133 sd 165 136 sd 102.7 1973 sd 1485
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Table 3.3 : Protease Inhibitors (mean and standard deviation)
Parameter Healthy Gingivitis Periodontitis
Alpha 1 antitrypsin 
(ng/30s)
112.5 sd 138.3 485 sd 403 707 sd 448
Alpha 1 antitrypsin 
(ng/uL/30s)
2615 sd 3616 4993 sd 5766 3469 sd 5639
Alpha 2
macroglobulin
(ng/30s)
46.4 sd 56.3 594 sd 595 636 sd 1041
Alpha 2
macroglobulin
(ng/uL/30s)
1076 sd 1531 10961 sd 23071 2163 sd 3010
Alpha 2
macroglobulin/ 
elastase ratio
72.4 sd 82.5 858 sd 708 2829 sd 5301
Alpha 1 anti 
trypsin/ elastase 
ratio
179.2 sd 261.3 728 sd 565 2464 sd 565
Alpha 1 anti 
trypsin/ alpha 2 
macroglobulin 
ratio
2.61 sd 1.676 1.264 sd 0.909 3.16 sd 3.63
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Table 3.4 Correlations of markers
Alpha 1
anti
trypsin
Alpha 2 
macroglobulin
Lactoferrin GCF
volume
Alpha 1 
antitrypsin
<0.4 0.861 0.572 0.636
Alpha 2 
macroglobulin
0.861 <0.4 <0.4 0.454
Elastase 0.582 0.377 <0.4 <0.4
Pocket Depth 0.610 0.430 0.626 0.708
Lactoferrin 0.572 <0.4 <0.4 0.697
GCF volume 0.636 0.454 0.697 <0.4
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CHAPTER 4
DISCUSSION
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4.1 Study Design Considerations
The principal aim of the study was to investigate potential differences in PMN granule 
components and levels of protease inhibitors in GCF at sites of periodontitis compared 
with health and gingivitis, with a view to highlighting site related differences. With that in 
mind a cross sectional study design was chosen.
Cross sectional studies collect information at one time point, at several different sites 
which are related. In this study the clinical characteristics determined the classification of 
the site on entry. The aim of site and candidate selection was to select periodontally 
active and undisturbed sites to compare with shallow inflamed and non inflamed sites. 
Sites which were designated as periodontitis sites on the basis of bone loss and pocket 
depth had marginal gingivitis and exhibited bleeding on probing to the base of the crevice. 
These clinical indicators were used as the best indicators of ongoing disease activity (Lang 
et al 1986). Candidates for sampling had received no periodontal interventions in the 
preceding 3 months. This reduced the potential for conditions in the gingival crevice to be 
influenced by instrumentation which affects GCF composition (Skapski and Lehner 
1976). Finally, by collecting related groups of samples from sites within individuals some 
of the compounding effects of systemic related variants, such as tobacco smoking, 
diabetes and drug therapy were reduced.
In the study of PMN function in periodontal diseases peripheral blood is often used due 
to the difficulty in collection and retrieval of crevicular PMNs. As discussed by Wilton 
(1989) these peripheral blood PMNs may not be representative of those in the crevice, 
especially in view of the site specific nature of disease which is clinically observed 
(Socransky et al 1987). As a result it may be inappropriate to extrapolate from in vitro 
findings with peripheral blood PMNs, as has been done (Gustafsson et al 1994), to the in
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vivo situation of the gingival crevice. Thus, in the study of PMN dynamics, locally 
collected PMN markers were assayed.
As the study involved the examination by ELISA of 4 GCF components, including 
protease inhibitors, a GCF paper strip sampling technique, rather than a gingival washing 
technique was used to collect samples as it is reliable and relatively easy to perform.
Every effort was made during sample collection to obtain uncontaminated strips for the 
laboratory studies. This was achieved by isolating teeth during sampling and by discarding 
strips visibly contaminated with blood.
4.2 Choice of Laboratory Methods
Three of the assays had been developed and validated previously in our laboratory, the 
assays for lactoferrin, alpha 1 anti trypsin and alpha 2 macroglobulin (Adonogianaki 
1992). As will be discussed later, the final assay for elastase was developed for the 
present study.
Most studies relating to GCF elastase measure elastase-like activity rather than the 
antigenic elastase levels. As the study was attempting to compare primary and secondary 
PMN granule components it was appropriate that the same method of assaying be used 
for both. Such measurement is complicated by the binding of elastase to protease 
inhibitors in GCF, which means that the level of elastase recorded may not directly reflect 
that released by PMNs. However, the measurement of elastase-like activity in GCF is 
also complicated by problems of potential cross reaction of other proteases with the 
experimental substrate. What would be ideal would be the combined measurement of 
antigenic elastase and elastase- like activity in the same sample (Cox 1995). Combination 
assays of that nature however encounter problems relating to the suitability of elution
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techniques for each of the different assays used, which to some extent was the case with 
the assay developed for elastase. This approach may necessitate the collection of more 
than one GCF sample at each site, the composition of these samples would not be similar 
(Skapski and Lehner 1976).
The ELISA technique was used to assay for all GCF markers. ELISA is a technique by 
which antibody combined with antigen is detected following conjugation with a 
colourometric substrate. The colour change is monitored visually and correlates with the 
amount of antigen present in the original sample. Non competitive assays involve the use of 
antigen or antibody coated onto the solid phase. The final antibody is labelled to react with 
the substance used for visualisation in the system. The solid phase is generally a plastic, 
either polystyrene or PVC, available as plates or beads.
The level of marker recorded by ELISA is a measure of the amount of antigenic material 
detected in the sample. With regard to PMN granule components this is potentially from 
several sources. It may be from granule contents released in the gingival connective tissues 
and diffusing into the gingival crevice; from granule contents released into the gingival 
crevice prior to sampling; and from granules which are disrupted either during GCF 
collection or during the preparation and storage of samples. It was assumed that the 
amount of disruption caused to the PMN during sample elution involving the use of 
buffer containing TWEEN, which is a detergent, would affect primary and secondary 
granules in a similar way. This may not be the case. However any differential release of 
granular components during collection, elution and storage is not easily quantifiable using 
standard GCF collection methods. This is because GCF contains not only tissue and cell 
products but intact and functional cells which can be disrupted at any stage during 
handling.
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Initially a sandwich ELISA for elastase was attempted. These assays have the advantage 
of being more sensitive and specific. In addition, following collection of samples GCF was 
eluted into incubation buffer prior to storage rather than into coating buffer. During its 
development several problems were encountered. The sources of PMN elastase antibodies 
were extremely limited and we were unable to locate two separate antibodies that could be 
used for ELISA. As a result we prepared a biotinylated anti PMN elastase and developed 
a sandwich ELISA utilising this as a second antibody. This biotinylated antibody was 
extremely unstable. By the time the working range for each new batch of antibody had 
been determined the antibody was no longer active. Plate readings for clinical samples 
using the biotinylated antibody were either extremely low or not detectable.
To overcome these problems ah assay was developed using GCF samples as coating 
agents. The reduction in detectability was determined by comparing readings of purified 
antibody in coating buffer and incubation buffer eluted from paper strips. These eluted 
samples were then coated onto plates and used in the assay under the same conditions. 
This showed an average reduction in recovery of elastase to around 2.7%. In a recent 
paper Gustafsson (1996) reported that he had failed to recover uncomplexed PMN 
elastase from Periopapers. The present study recovered some PMN elastase, but like the 
study of Gustafsson (1996) this was much less than for other proteins examined. This 
greatly reduced sensitivity in the detection of elastase is a weakness, however the levels of 
elastase recorded were still within the working range of the assay. In addition, the elution 
pattern from paper strips of a commercially pure PMN elastase may not accurately 
reflect that of PMN elastase in GCF. In the reporting of the results elastase was, as a 
result, examined with most interest as it related to other agents assayed.
The problems in the measurement of elastase by ELISA of its potential to bind to 
inhibitors in GCF could not be fully addressed by the sampling and assaying techniques 
used. As a result of the assay technique used, it is not possible to say what combination 
of elastase and inhibitor or pure elastase is being detected. If an alternative marker of
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primary granules is not used, a future study should assess the detection rate of purified 
elastase and inhibitors in varying concentrations. This would enable further understanding 
of the dynamics, in vitro, of the binding of elastase to its inhibitors. Nevertheless, even 
when elastase inhibitor combinations are determined in vitro, elastase in vivo may be 
bound to other inhibitory molecules (Remold-O’Donnell et al 1989).
4.3 Primary and Secondary granule markers in GCF
We found a statistically significant increase in the absolute amount of lactoferrin in GCF 
between healthy and periodontitis sites but no difference in the concentration of 
lactoferrin. at.any category of site. The level- of lactoferrin recorded at healthy and 
gingivitis sites was similar to those previously recorded (Adonogianaki et al 1993). The 
high correlations between lactoferrin, pocket depth and GCF volume is similar to that 
study. Lactoferrin in GCF has not been studied extensively but has been proposed as a 
marker of activated PMN migration from vessels into GCF (Adonogianaki et al 1993, 
Gustafsson et al 1994). Adonogianaki et al (1994) further examined the profile of 
lactoferrin in experimental gingivitis. They found a statistically significant increase in 
lactoferrin as inflammation developed and a rapid decrease once oral hygiene was resumed. 
They related this rapid drop to the removal of plaque and the resultant decrease in the 
chemotactic stimulus for PMN migration into the gingival crevice. For the purposes of 
this discussion lactoferrin is taken to reflect the number of PMNs present in the crevice at 
the time of sampling.
Elastase levels, measured by ELISA, in GCF reflect the amount of antigenic elastase 
present rather than its activity. These antigenic levels have not been studied often in GCF. 
The present study detected no statistically significant difference in either absolute 
amounts or concentrations of elastase in relation to inflammation or pocket depth. There
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was, however, a tendancy for elastase levels to be higher at healthy and gingivitis sites. A 
possible mechanism for this will be proposed later.
Gustafsson et al (1992) examined the relationship of antigenic elastase and elastase 
activity in GCF using a substrate in two groups of patients; those with gingivitis and 
those with periodontitis. This study has the drawback of comparing two groups of 
patients rather than two types of sites within an individual. As a result it may be affected 
by the potentially large systemic variations which were to some extent avoided in the 
present study. In their reporting of differences between groups, the averages from two 
separate and unrelated sites were reported. They showed significantly higher 
concentrations and absolute amounts of elastase activity in patients with periodontitis. 
They did riot however find any difference in either the absolute amount or concentration 
of antigenic elastase at the two types of site. In their study they attributed the lack of 
difference in antigenic elastase to the difficulties in relating clinical parameters to 
inflammation and assumed that elastase was related directly to the number of crevicular 
PMNs.
Meyle et al (1992) examined the amount of antigenic elastase in subjects following 
intensive oral hygiene and found no difference in the concentration of the complexed form 
of elastase i.e. that bound to alpha 1 antitrypsin, in relation to an improvement in oral 
hygiene. They did, however, find a significant difference in the amount of functional 
elastase, with a reduction during the improvement of oral hygiene. This they measured by 
adding pooled serum to the GCF samples. Unbound elastase was thus complexed with 
free alpha 1 antitrypsin in the serum and could be identified by the ELISA used. They 
reported functional elastase, proposing that it was free and unbound, as the difference 
between the complexed elastase in GCF and the total amount recorded after saturation 
with alpha 1 antitrypsin from serum. Using this method they concluded that antigenic and 
functional elastase activity in GCF did not follow the same pattern. No explanation for 
the lack of change in antigenic elastase was proposed, however they did speculate that the
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increased level of functional elastase at inflamed sites was due to a deficiency of alpha 1 
anti trypsin.
It is possible that in the present study, by measuring elastase in GCF using the ELISA 
technique we are recording differences similar to those observed by Gustafsson et al 
(1992) and Meyle et al (1992).
Alavi et al (1995) again attempted to address this discrepancy between functional and 
antigenic elastase at periodontal sites. They measured levels of antigenic and functional 
elastase in matched groups of smokers and non smokers. This study has the advantage of 
attempting to examine matched sites with regard to elastase activity and antigenicity and 
thus, if widely applied, overcomes the problems as outlined by Cox (1995). They 
collected GCF using Durapore filter strips, which enable the release and study of intact 
PMNs from the crevice. As a result they were able to perform GCF PMN counts in 
addition to the assays for antigenic and functional elastase. They found that the 
concentration of elastase in antigenic and functional forms was lower in smokers than in 
non smokers. They speculated that the increased level of tissue breakdown in smokers 
was not related to increases in elastase activity but may be attributed again to alterations 
in the binding of elastase to alpha 1 anti trypsin, as is seen in lung disease.
There appears to be a discrepancy between in vivo clinical findings with respect to 
elastase. Studies using elastase substrate assays provide evidence that elastase activity 
increases in GCF in gingivitis and at inflamed sites (Gianopoulou et al 1992, Darany et al 
1992, Eley and Cox 1992, Smith et al 1995); in sites losing attachment (Palcanis et al 
1992, Armitage et al 1994, Jin et al 1995); and that it decreases in response to basic, 
successful periodontal treatment (Cox and Eley 1992). These findings have been proposed 
as evidence for an increased release of elastase from PMNs at diseased sites. In none of 
these studies was the number of PMNs in GCF examined, nor was a cellular marker for
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PMNs in GCF, such as lactoferrin, assayed. It was also assumed that functional elastase 
equated with that released from PMNs, Gustafsson et al (1992) and Meyle et al (1992) 
have shown that this may not be the case. It would seem logical that at sites of tissue 
destruction protease activity is higher, but it is possible that this is not due solely to an 
increase in the release of PMN granular proteases at these sites. The relative release of 
primary and secondary PMN granule components in the GCF samples was examined.
The results support release of both primary and secondary PMN granule products into 
GCF at sites of periodontal health, gingivitis and periodontitis. In addition it is shown 
that a differential primary and secondary granule release occurs in healthy, gingivitis and 
periodontitis sites. There is a 10 fold relative increase in the amount of lactoferrin detected 
at periodontally involved sites. This difference may be accounted for by; 1) a relative 
decrease in the degranulation of primary granules, or 2) a relative increase in degranulation 
of secondary granules at periodontitis site.
The study detected no significant differences in either absolute amount or concentration of 
elastase at any category of site, indeed the amount of elastase appeared to be slightly 
higher at gingivitis sites than periodontitis sites. With regard to lactoferrin release, an 
increase in absolute amounts but not concentration was seen in periodontitis sites in 
comparison with gingivitis sites.
If release from primary and secondary granules is the same in all types of periodontal 
sites, it would be expected that the absolute amount of each granule component in GCF 
would increase in line with the volume of GCF and the number of PMNs, as is the case 
with lactoferrin. The finding that there is no increase in the absolute amount of elastase, 
despite the fact that the GCF volume and the number of PMNs are increased supports 
the former proposal i.e. that there is a relative decrease in the degranulation of primary 
granules at sites of periodontitis. This is in contrast to the findings of Gustafsson et al 
(1994) who proposed an exuberant degranulation of primary granules indicated by an 
increase in elastase activity relative to lactoferrin in inflamed crevices. Again this may be a
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manifestation of the lack of a direct relationship between elastase like activity, measured 
by protease substrates in GCF, and the actual release of elastase from primary granules.
Alterations in PMN dynamics may be due to changes related to either phagocytosis or to 
the PMN response to immune complexes and immunoglobulins in the gingival crevice, as 
discussed in Chapter 1. Degranulation of PMNs generally occurs intracellularly into 
phagosomes, however there are mechanisms by which the contents are released 
extracellularly. These mechanisms are by cell death, perforation from within, regurgitation 
during feeding and reverse endocytosis (Goldstein 1984).
When release is. by cell death this is generally as a consequence of cell damage by toxins or 
by injury. Damage to the plasma membrane causes the cell to rupture and release its 
contents into the surrounding medium. In such cases it would be expected to find equal 
proportions of all granule products as the whole cell is disrupted.
Perforation from within is a consequence of material in the interior of the cell directly 
rupturing lysosomal membranes. As cells die their contents are released extracellularly. 
Again, it would be expected that equal amounts of all markers would be present in this 
circumstance.
Regurgitation during feeding (Weissmann et al 1972) is the process whereby cells engaging 
in phagocytosis release some of their lysosomal products extracellularly from 
incompletely enclosed phagosomes. This is not accompanied by cell death and the cell 
remains viable. In this situation one would expect to find alterations in the content of the 
extracellular fluid in relation to the components involved in degranulation associated with 
phagocytosis
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Finally, degranulation occurs without phagocytosis i.e. by reverse endocytosis. In this 
case neutrophils encountering immune complexes or immunoglobulins on solid surfaces 
adhere to the surface and release their granule contents directly into the extracellular 
environment (Goldstein 1976, Weissmann 1971).
Since PMNs collected from GCF are predominantly viable (Skapski and Lehner 1976, 
Kowolik and Raeburn 1980, Murray and Patters 1980, Charon et al 1982) the two 
mechanisms by which their granule contents are likely to be found in GCF are by 
regurgitation during feeding or by reverse endocytosis.
The degranulation of primary and secondary granules is under separate control (Henson 
1971, Bentwood and Henson 1980, Murphy and Hart 1987,) with secretagogues effecting 
degranulation of either primary or secondary granules exclusively or preferentially (Boxer 
and Smolen 1988). Gustafsson et al (1994) reported degranulation assays using peripheral 
blood PMNs and opsonised Staphylococcus aureus. He confirmed the findings of others 
that PMN degranulation in respect of primary and secondary granules is separate in time 
and rate and proposed that in the gingival crevice PMNs were in an activated state at deep 
sites. However the degranulation assay which they used is not directly relevant to the 
situation in a periodontal pocket. Staphylococcus aureus, is not a micro-organism which is 
related to periodontal tissue destruction (Socransky and Haffajee 1992). In addition the 
bacteria were opsonised by human gamma globulin prior to incubation, as discussed below 
this mechanism may not be fully functional in relation to the gingival pocket. The cellular 
mechanisms which control these neutrophil secretions are only generally understood with 
G protein phosphorylation, protein kinase activity and changes in intracellular calcium 
being proposed (Fittschen and Henson 1994).
A decrease in degranulation of primary PMN granules has been described in several 
circumstances relating to infectious diseases. Evidence relates to the alteration in the
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normal, separate control of degranulation effected by bacteria, viruses or infectious agent 
products. Quie (1983) reviewed inhibition of lysosome-phagosome fusion in relation to 
Mycobacterium tuberculosis, Histoplasma capsulatum, toxiplasma gondii, Chlamydia and 
some strains of Neisseria gonorrheae. This inhibition of degranulation occurs in the 
presence of normal PMN chemotaxis and phagocytosis.
Following phagocytosis of Brucella abortus, primary granule release is preferentially 
inhibited (Riley and Robertson 1984). In their study they showed that smooth and rough 
strains of Brucella abortus were both ingested normally but the smooth strain failed to 
stimulate primary degranulation after ingestion. This inhibition was related to a cell wall 
LPS. The result of failure to stimulate degranulation is decreased killing of ingested 
bacteria arid increased pathogenicity. Bertram et al (1986) carried out further in vitro work 
on a Brucella abortus extract confirming inhibition of primary granule release and 
suggested that the inhibition was dose dependent relating to a nucleotide like material.
Inhibition of lysosome-phagosome fusion has been shown in vitro in relation to influenza 
virus and has been proposed as a factor in the increased susceptibility to bacterial 
infection coincident with influenza infection. Abramson et al (1982) showed that virus, or 
virus associated products, inhibit fusion of primary granules with phagosomes containing 
bacteria, the inhibition of that fusion correlates with decreased bacteriocidal activity.
Scrapie prion protein was shown to inhibit degranulation of primary granules of PMNs 
when in the native but not denatured form (Miragliotta 1989). They related this to a 
sialoglycoprotein macromolecule within the prion.
The differential release of granule constituents in relation to periodontally associated 
bacteria has not been much investigated. Baehni et al (1978) exposed peripheral blood
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PMNs to supra and subgingival plaque and recorded the release of lysosomal markers. In 
addition they examined the ultrastructure of the PMNs during the experiment. They 
reported phagocytosis of micro-organisms and lysosomal degranulation. Their in vitro 
study showed an increased release of the lysosomal markers, lysozyme, B-glucuronidase, 
myeloperoxidase and lactoferrin in response to supragingival plaque compared with 
subgingival plaque.
Taichman et al (1977) exposed PMNs to irradiated plaque and recorded dose dependent 
PMN granule product release. The differences observed with viable plaque from supra 
and subgingval sites were absent. In all cases the addition of serum to the reaction mixture 
increased release from PMNs. On the basis of this serum dependant change they 
speculated that in the gingival crevice, PMNs release granule products by mechanisms 
that are not dependent on phagocytosis i.e. by reverse endocytosis mediated by 
complement or immunoglobulins. They further postulated that these mechanisms of 
degranulation are important in the extracellular killing of bacteria. This concept was 
supported by Wilton (1982) who proposed that complement fragments and 
immunoglobulins are important mediators of degranulation in the gingival crevice.
Although phagocytosis of plaque micro-organisms in the gingival crevice has been 
observed by many workers (Baehni et al 1978, Attstrom 1970) it is not the exclusive 
relationship of PMNs to micro-organisms. Tsai et al (1977) reported release of lysosomal 
enzymes in response to dental plaque which was independent of phagocytosis. Wilton 
(1986) suggested that phagocytosis was only likely for unattached fluid phase bacteria. 
Degranulation of PMNs was stimulated not only by phagocytosis but by other 
components of GCF, notably complement fractions C5a, C3b, C4b, immune complexes, 
bacterial toxins, IL-1 and by PMN migration. He proposed that since secondary granules 
were more abundant, and that release of their contents was more rapid and complete, it 
was possible that only these granules were released in the crevice.
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The present study does not support only the release from secondary granules but does 
appear to show that at deeper, periodontally involved sites their release is not reduced in 
the manner of that from primary granules.
Taichman and McArthur (1976) proposed that not all periodontal bacteria stimulate 
lysosome release and related this ability to the synthesis of extracellular polysaccharides, 
as has been discussed in relation to other infectious agents above. Novak and Cohen 
(1991) reported a membrane depolarising agent associated with the capsule of some 
strains of Porphyromonas gingivalis which fails to initiate increases in intracellular 
calcium or to activate the respiratory burst. They suggested that this immobilises PMNs 
local activity and is an important virulence factor.
Thus from the evidence above it appears that if phagocytosis is not resisted bacteria may 
have an innate ability to suppress degranulation of primary granules. Alternately, co­
incidental viral infection may affect degranulation. The results presented from this study 
may be an in vivo finding of the failure of periodontal pathogens to activate PMNs in the 
gingival crevice to produce reactive oxygen species and to degranulate.
When phagocytosis is not the most important mechanism for the control of micro­
organisms, as is proposed in the gingival crevice, the alternative delivery of PMN primary 
granule contents is by reverse endocytosis. Reverse endocytosis is mediated by 
complememt and immune complexes binding to the surface of the PMN.
Arnold (1993) reported that even for patients with high antibody titres to 
Porphyromonas gingivalis antibody may not be opsonic and protease production by this 
bacteria may neutralise not only antibody but also complement. Kinane et al (1993) 
studied the level of IgG to P. gingivalis in periodontal pockets of different depths and
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found that in deep pockets the level of antibody was reduced. Lopatin et al (1991) 
suggested that even in the presence of high antibody titres the avidity i.e. overall biological 
activity of the antibody in periodontitis sites may be low and thus contribute to the 
decreased elimination of bacteria and potentiate disease. Mooney et al (1993) studied a 
group of patients on a periodontal maintenance programme and compared the antibody 
titre and avidity in patients losing attachment and those not losing attachment over the 
study period. They showed that subjects losing attachment had lower baseline IgM 
avidity to Porphyromonas gingivalis than those who did not lose attachment. Cutler et al 
(1991) showed that effective binding of IgG to Porphyromonas gingivalis was essential in 
the opsonisation and phagocytosis of this organism and in complement activation.
In summary, it has been shown that local antibody levels are lower in deeper pockets and 
in inflamed sites than in shallower sites with less inflammation. Reverse endocytosis is 
dependent on these antibodies and complememt for opsonisation. Thus a reduction in the 
level or avidity of antibody or the destruction of complement by pathogens may be 
reflected by a decrease in primary granule degranulation and a relative weakening of the 
PMN defence in the area. There is the potential in the gingival crevice for phagocytosis 
and degranulation, either separately or together, to be disrupted, for local antibody to be 
ineffective due to its initial low titre and avidity in deep pockets and also for complement 
to be locally destroyed. In the face of the local paralysis of the PMN, bacteria have an 
increased opportunity to destroy tissue. With treatment the local bacterial challenge is 
reduced. This reduction encourages the production of antibody of higher avidity and 
biological function is improved. In addition complement is not degraded by bacterial 
proteases to the same extent and thus is more efficient in the opsonisation of bacteria.
A possible explanation of the present findings is as follows. In shallow pockets there may 
be bacteria that provoke complement activation, to which there is an appropriate immune 
response and which if removed by phagocytosis provoke degranulation of primary 
granules. In deeper pockets with inflammation where there is a reduced local antibody
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level and antibody that is there is less effective in the activation of complement, less 
degranulation occurs. In addition those bacteria that are phagocytosed may not provoke 
the degranulation of primary granules. Thus the PMN response is reduced and bacteria 
can continue to function in tissue destruction.
4.4 Protease inhibitors in GCF
As previously discussed a fall in the relative degranulation from primary granules is in 
apparent conflict with the recorded increase in elastase activity in GCF at sites of 
inflammation reported by others. Alterations in the elastase activity recorded may be 
attributable to changes in binding of elastase to its major inhibitors, alpha 1 antitrypsin 
and alpha 2 macroglobulin. With alpha 1 antitrypsin protease inhibition is complete 
whereas with alpha 2 macroglobulin inhibition is incomplete. One possible explanation is 
that in disease states relatively more elastase is bound to alpha 2 macroglobulin than alpha 
1 antitrypsin thereby increasing the residual protease activity of GCF.
Alpha 1 antitrypsin has been identified as of importance in clinical medicine (Kalsheker 
1994) in relation to pulmonary disease and liver cirrhosis. It is proposed that a reduction 
in alpha 1 antitrypsin results in a loss of the antielastase shield in the lung and that this 
imbalance is the cause of early lung damage in individuals with alpha 1 antitrypsin 
deficiency. Like the lung the gingival crevice has a capillary bed with a tissue interface that 
is subject to bacterial and protease attack. Alavi et al (1995) proposed that alpha 1 
antitrypsin may be of similar importance in the gingival crevice. However in the present 
study the absolute amount of alpha 1 antitrypsin was significantly increased not 
decreased at gingivitis and periodontitis sites relative to healthy sites. No significant 
differences were recorded in relation to its concentration.
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Alpha 1 antitrypsin may have other functions in GCF. Various concentrations have been 
examined for the ability to promote PMN chemotaxis (Aoshiba et al 1993). They showed 
that the inhibitor was capable of causing in vitro chemotaxis and chemokinesis at 
concentrations of 0.02mg/mL, 0.2mg/mL and 2mg/mL, with maximum potency at 2mg/mL. 
Above that level, up to lOmg/mL, chemotaxis of PMNs in response to known 
chemoattractants was inhibited. They hypothesised that alpha 1 anti trypsin had a 
regulatory role on PMN recruitment at sites of inflammation whereby at 0.2mg/mL the 
concentration found in alveolar fluid in the lung PMNs were attracted to protect the 
airways. The 2mg/mL in blood was sufficient to prevent excessive loss of PMNs from the 
circulation.
The mean concentration of alpha 1 anti trypsin at healthy sites was 2615ng/ul (range 35- 
10176, SD 3616), at gingivitis sites 4993ng/ul (range 941-20774, SD 5766) and at 
periodontitis sites 3469ng/ul (range 678-19362, SD 5639). This equates to 2.615mg/mL, 
4.993mg/mL and 3.469mg/mL respectively. Bearing in mind the inaccuracies in recording 
concentrations of GCF components and the fact that these average values are higher by a 
factor of ten than was recorded by Adonogianaki et al (1992), concentrations of alpha 1 
antitrypsin found in the gingival crevice probably fall into the range in which chemotaxis 
and chemokinesis is promoted. The level of correlation of alpha 1 antitrypsin with 
elastase and lactoferrin further support this possible mechanism in the gingival crevice. If 
this system is operational alpha 1 antitrypsin may play a crucial role in the control of 
PMN movement towards the gingival crevice.
In relation to alpha 2 macroglobulin in GCF the absolute amount recovered rose sharply 
with inflammation and was significantly higher in gingivitis and periodontitis sites relative 
to healthy. With regard to the concentration of alpha 2 macroglobulin, this rose at 
gingivitis sites which were significantly different from healthy sites but not from 
periodontitis sites.
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Sengupta et al (1988) found lower levels of alpha 2 macroglobulin after the improvement 
of clinical parameters. In contrast Skaleric et al (1986) found lower levels of alpha 2 
macroglobulin at sites with a history of alveolar bone loss and with inflammation. This 
difference may be due to collection and reporting methods. They collected GCF of a 
predetermined volume using microcapillary tubes, this is traumatic to tissues (Cimasoni 
1983) and causes dilution of the components in the crevice as a result of increasing 
vascular permeability. In addition all values were expressed in concentrations which again 
may be less reliable means of presentation for samples (Lamster et al 1986).
Studies examining both inhibitors in the same sample tend to have similar findings. Levels 
recorded in the present study follow the pattern previously described using the same 
assay with GCF in a cross sectional trial (Adonogianaki et al 1992). They found higher 
absolute amounts of alpha 1 antitrypsin and alpha 2 macroglobulin at inflamed and deep 
sites compared with healthy sites. In relation to alpha 1 antitrypsin the current levels are 
higher than previously recorded. This increase is likely due to the very wide range of 
values recorded for alpha 1 antitrypsin and the relatively small number of samples in the 
present study.
In their study of healthy and periodontally involved teeth Ohlsson et al (1974) found 
alpha 1 antitrypsin and alpha 2 macroglobulin in the gingival crevice at sites of both health 
and disease. They reported that the level of both inhibitors was higher at sites of 
inflammation and that alpha 1 antitrypsin was saturated with respect to its protease 
inhibiting capacity. Adonogianaki et al (1994) demonstrated an increase in the inhibitors 
alpha 1 antitrypsin and alpha 2 macroglobulin over a 21 day experimental gingivitis 
period. They attributed this to the increase in serum derived inhibitor and also an increase 
in the local production of alpha 2 macroglobulin from fibroblasts, alpha 1 antitrypsin and 
alpha 2 macroglobulin from monocytes and macrophages and alpha 1 antitrypsin from 
PMNs.
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In experimental gingivitis trials what is being examined is change in site characteristics 
when comparing sites with no inflammation and sites with inflammation. What is 
ultimately clinically useful is to differentiate between sites which are periodontally active 
and those which are not. In a prospective study addressing this issue Adonogianaki et al 
(1996) examined the ability of the acute phase proteins, including alpha 1 antitrypsin, 
alpha 2 macroglobulin and lactoferrin, to identify active and stable sites in periodontal 
maintenance patients. They found that the 3 markers could not discriminate between sites 
at baseline on the basis of attachment loss. Probing attachment loss was not preceded by a 
change in these markers and they proposed that they were all markers of gingival 
inflammation rather than destruction. In addition they proposed that exuberant PMN 
activity, if measured by lactoferrin, was not a feature of periodontally active sites.
Thus, the present study is in line with others in finding alpha 1 antitrypsin and alpha 2 
macroglobulin in GCF. It is also in agreement that the level of both inhibitors increases at 
sites of inflammation. In addition it confirms other work that neither the absolute amount 
or concentration of either of these inhibitors can differentiate gingivitis and periodontitis 
sites (Adonogianaki et al 1992).
The present study showed a tendency for the level of alpha 1 antitrypsin relative to alpha 
2 macroglobulin to be increased at healthy and periodontitis sites compared with gingivitis 
sites, this difference did not reach significance. There was a high correlation between alpha 
1 antitrypsin and alpha 2 macroglobulin. Thus a shift in the importance of either the 
complete inhibition of elastase, alpha 1 antitrypsin, at sites of health to increased relative 
inhibition by alpha 2 macroglobulin at diseased sites is not supported. In addition the 
pattern of change in inhibitors from one site to another was similar in 7 of the 10 subjects 
from whom GCF was collected.
97
Protease inhibitors in the GCF are derived from two sources; either from the serum or 
local cells among which are fibroblasts, monocytes, macrophages and PMNs. Condacci et 
al (1988) demonstrated the in vitro ability of gingival fibroblasts to synthesise alpha 2 
macroglobulin. In a further clinical study the group examined the relationship of alpha 2 
macroglobulin to albumin during experimentally induced gingivitis. In the study albumin 
was used as a marker of serum derived protein. They found that the concentration of 
albumin increased two fold during the experimental period and the concentration of alpha 
2 macroglobulin by around six fold. They attributed this increase in alpha 2 macroglobulin 
to both increased passage of inhibitor from the blood vessels and local production.
Since the local sources of inhibitors are different and since the pattern of change observed 
is similar in the majority of cases, it would seem unlikely that in vivo local production of 
inhibitors is contributing greatly to the GCF pool. This is in agreement with the proposals 
of Lamster et al (1990) and Adonogianaki et al (1996). Alternatively local production of 
inhibitors may be largely confined to and important in, the connective tissue interface.
4.5 Elastase and Protease inhibitors in GCF
The level of alpha 1 antitrypsin relative to elastase increased significantly from healthy to 
gingivitis and periodontitis sites. This does not support the idea that increased elastase 
activity is due to a lack of alpha 1 antitrypsin or a shift away from effective protease 
inhibition as is seen in the lung. It also further reinforces the host attempt at protection in 
deep and inflamed pockets and may be a manifestation of the local production of inhibitor 
in the increased number of PMNs.
du Bois et al (1991) recently demonstrated expression by PMNs of the gene for alpha 1 
antitrypsin and confirmed the ability of the cells to produce the inhibitor. This gives
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neutrophils the potential to protect the local environment from the damaging effects of 
their secreted proteases, although the contribution from this source to body fluids is still 
thought to be less than that from hepatocytes and monocytes. They postulated that the 
role of locally, PMN produced, alpha 1 antitrypsin was in the inhibition of elastase from 
PMNs adherent to surfaces where systemically derived inhibitors are thought to have 
little effect. They further postulated that in circumstances where neutrophils are not 
releasing major amounts of elastase this mechanism may be efficient in the inhibition. 
However, where large amounts of elastase are released or at fluid interfaces oxidants 
produced by the neutrophils and the absolute amount of released protease would 
overcome the defence. They suggested that this mechanism protects host tissue from 
protease degradation during PMN migration through tissues. This may be a mechanism 
operational in healthy gingival crevices and tissue where elastase is found, but where it 
appears that there is effective inhibition of tissue destruction.
Alpha 1 antitrypsin inactivation occurs in the presence of oxidants (Weiss 1989) and has 
recently been shown to be caused also by metallo-proteinases in myeloperoxidase 
positive granules (Ottonello et al 1994). Although data in the study is not available 
regarding the state of activity of either elastase or its inhibitors, a possible explanation for 
the increase found in elastase activity despite a relative decrease in the degranulation of 
PMNs may be as follows. At deeper sites with inflammation there may be more 
inactivation of the inhibitor by oxidants generated in the respiratory burst or by other 
granule components. Alternatively the local source of alpha 1 antitrypsin as described by 
du Bois may be overcome thus enabling increased local protease activity.
With reference to alpha 2 macroglobulin relative to elastase levels rose from health through 
to periodontitis. Significant differences were observed between shallow non inflamed sites 
and inflamed sites but not shallow and deep inflamed sites i.e. gingivitis and periodontitis 
sites. One possibility, that the amount of alpha 2 macroglobulin increases thus causing 
incomplete protease inhibition at deep sites with active destruction, is not supported. In
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addition the increase in the level of inhibitor relative to protease again suggests an attempt 
to protect host tissues.
Using a patient profile similar to that reported previously, Gustafsson et al (1994) 
studied elastase activity and alpha 2 macroglobulin in GCF of gingivitis and periodontitis 
patients. They reported higher amounts of elastase activity and lower alpha 2 
macroglobulin levels at sites with destruction compared with those with only superficial 
inflammation. This is in contrast to the findings with regard to the present study which 
detected higher levels of inhibitor and a higher ratio of inhibitor to antigenic elastase at 
inflamed sites. Again they proposed that this was attributed to increased numbers of 
crevicular PMNs and that these were in an activated state. They proposed that lower 
levels of alpha 2 macroglobulin were found because of its increased consumption by 
proteases and its subsequent uptake in the reticulo-endothelial system. It may be that in 
this study by the reporting of concentrations they are incorporating differences related to 
the increased volume of GCF at deep sites in relation to alpha 2 macroglobulin.
Giannopoulou et al (1992) in the experimental gingivitis study previously described found 
that both the total amount and concentration of inhibitors rose significantly during the 
development of inflammation. Their assays demonstrated that antigenic elastase in the 
GCF eluted with alpha 1 antitrypsin and functional elastase with alpha 2 macroglobulin. 
The present study concurs with their finding of a rise in elastase and its inhibitors at sites 
of inflammation.
As discussed previously many workers use fluorogenic substrates for the evaluation of 
elastase in GCF and equate elastase activity with the function of primary granules. Using 
these substrates they propose that there is an increase in the release of elastase from 
primary granules at sites of periodontal disease. In view of the elution of elastase with 
alpha 2 macroglobulin this may not be a valid assumption i.e. elastase activity is not due
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to free elastase. Instead, the activity of the elastase released by primary granules may be 
modified by other factors in the GCF thus accounting for the discrepancy between 
elastase and elastase like activity changes.
A study reported by Rosin et al (1995) supports this proposal. They studied the level of 
complexed alpha 2 macroglobulin and the total amount of alpha 2 macroglobulin in 
shallow and deep periodontal pockets. They showed no change in concentration of these 
two forms between shallow and deep sites. They found that the total alpha 2 
macroglobulin was related to protease activity in GCF and inflammation and that at all 
sites around 70% of alpha 2 macroglobulin was present in the complexed form, with no 
difference between shallow and deep sites. They showed no correlation between the 
complexed form of inhibitor and protease activity at shallow sites. They suggested that 
the amount of complexed inhibitor was related not only to the protease load in GCF but 
also to the conversion of alpha 2 macroglobulin by bacterial end products, the presence of 
matrix metalloproteinases and complexed inhibitor entering the GCF as a result of normal 
tissue turnover.
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4.6 Conclusions
1 The previous findings of Adonogianaki et al (1993) that lactoferrin correlates with 
pocket depth and GCF volume are supported.
2 It is proposed that the independent measurement of elastase activity may not be an 
indicator of crevicular PMN function.
3 The alteration in the relationship of the primary PMN granule marker elastase and the 
secondary granule marker lactoferrin may be of clinical use in the differentiation of 
gingivitis and periodontitis.
4 A mechanism involving the local paralysis of PMN function in deep pockets is 
proposed. This would effectively disable the cells and prevent them from releasing 
granule contents which may protect the host by eliminating destructive bacteria.
5 The levels of protease inhibitors alpha 1 antitrypsin and alpha 2 macroglobulin were 
not reduced at sites of periodontitis. The levels of these 2 inhibitors had a high 
correlation, r=0.861. This would tend to support the principle source of these 
inhibitors in GCF being the same.
6 The increased breakdown in relation to periodontitis sites does not appear to be related 
to an alteration of the relative importance of either of the proteases measured in GCF.
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4.7 Future Work
The study presented could be viewed in the nature as pilot study. The most interesting 
aspect of this work is the difference in the level of degranulation for primary and 
secondary PMN granules at deep, inflamed sites. In view of the poor recovery of elastase 
from samples further studies need to incorporate:
• a larger number of subjects
• more than one area representing each type of site.
• an alternative PMN primary granule marker e.g. Beta glucuronidase, or attempt to 
refine a sandwich ELISA for PMN elastase.
• an assessment of functional and antigenic elastase and inhibitor complexes
Together these would provide more power to observe differences suggested by the pilot 
study.
In addition, it would be interesting to combine further study of degranulation dynamics 
with a study of the bacterial flora at the sampled sites. In the present study, the 
microbiology of sites was not assessed. Assumptions regarding the presence of particular 
periodontal pathogens at deep sites were made, particularly in relation to Porphyromonas 
gingivalis. In addition the continued study of inhibition of opsonisation and degranulation 
in relation to periodontal pathogens may give insight into the defence mechanisms 
operating in the gingival crevice.
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EPILOGUE
The Lotos blooms below the barren peak:
The Lotos blows by every winding creek:
All day the wind breathes low with mellower tone:
Thro every hollow cave and alley lone
Round and round the spicy downs the yellow Lotos-dust is blown.
We have had enough of action and of motion we,
Roll’d to starboard, roll’d to larboard, when the surge was seething free, 
Where the wallowing monster spouted his foam-fountains in the sea.
Let us swear an oath, and keep it with an equal mind,
In the hollow Lotos-land to live and lie reclined 
On the hills like Gods together, careless of mankind.
For they lie beside their nectar, and the bolts are hurl’d 
Far below them in the valleys, and the clouds are lightly curl’d 
Round their houses, girdled with the gleaming world:
Where they smile in secret, looking over wasted lands,
Blight and famine, plague and earthquake, roaring deeps and fiery sands, 
Clanging fights, and flaming towns, and sinking ships, and praying hands. 
But they smile, they find a music centred in a doleful song 
Steaming up, a lamentation and an ancient tale of wrong,
Like a tale of little meaning tho’ the words are strong;
Chanted from an ill-used race of men that cleave the soil,
Sow the seed, and reap the harvest with enduring toil,
Storing yearly little dues of wheat, and wine and oil;
Till they perish and they suffer - some, ‘tis whispered-down in hell 
Suffer endless anguish, others in Elysian valleys dwell,
Resting weary limbs at last on beds of asphodel.
Surely, surely slumber is more sweet than toil, the shore 
Than labour in deep mid-ocean, wind and wave and oar;
Oh rest ye, brother mariners, we will not wander more.
Tennyson
